

UnitedHealthcare of Louisiana, Inc.

Statutory Basis Financial Statements as of
and for the Years Ended December 31, 2020
and 2019, Supplemental Schedules as of and
for the Year Ended December 31, 2020,
Independent Auditors' Report and
Qualification Letter

UNITEDHEALTHCARE OF LOUISIANA, INC.

TABLE OF CONTENTS

	Page
INDEPENDENT AUDITORS' REPORT	1–2
STATUTORY BASIS FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019:	
Statutory Basis Statements of Admitted Assets, Liabilities, and Capital and Surplus	3
Statutory Basis Statements of Operations	4
Statutory Basis Statements of Changes in Capital and Surplus	5
Statutory Basis Statements of Cash Flows	6
Notes to Statutory Basis Financial Statements	7–55
SUPPLEMENTAL SCHEDULES AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2020:	
Exhibit I: Supplemental Investment Risks Interrogatories	
Exhibit II: Summary Investment Schedule	
Exhibit III: Supplemental Schedule Regarding Reinsurance Contracts with Risk-Limiting Features	
OTHER ATTACHMENT:	
Qualification Letter	

INDEPENDENT AUDITORS' REPORT

To the Audit Committee of
UnitedHealthcare of Louisiana, Inc.
3838 N. Causeway Boulevard, Suite 2600
Metairie, LA 70002

We have audited the accompanying statutory basis financial statements of UnitedHealthcare of Louisiana, Inc. (the "Company"), which comprise the statutory basis statements of admitted assets, liabilities, and capital and surplus as of December 31, 2020 and 2019, and the related statutory basis statements of operations, changes in capital and surplus, and cash flows for the years then ended, and the related notes to the statutory basis financial statements.

Management's Responsibility for the Statutory Basis Financial Statements

Management is responsible for the preparation and fair presentation of these statutory basis financial statements in accordance with the accounting practices prescribed or permitted by the Louisiana Department of Insurance. Management is also responsible for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these statutory basis financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the statutory basis financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the statutory basis financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the statutory basis financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the statutory basis financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the statutory basis financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the statutory basis financial statements referred to above present fairly, in all material respects, the admitted assets, liabilities, and capital and surplus of UnitedHealthcare of Louisiana, Inc. as of December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in accordance with the accounting practices prescribed or permitted by the Louisiana Department of Insurance described in Note 1 to the statutory basis financial statements.

Basis of Accounting


We draw attention to Note 1 of the statutory basis financial statements, which describes the basis of accounting. As described in Note 1 to the statutory basis financial statements, the statutory basis financial statements are prepared by UnitedHealthcare of Louisiana, Inc. using accounting practices prescribed or permitted by the Louisiana Department of Insurance, which is a basis of accounting other than accounting principles generally accepted in the United States of America, to meet the requirements of the Louisiana Department of Insurance. Our opinion is not modified with respect to this matter.

Report on Supplemental Schedules

Our 2020 audit was conducted for the purpose of forming an opinion on the 2020 statutory basis financial statements as a whole. The supplemental schedule of investment risks interrogatories and the supplemental summary investment schedule, and the supplemental schedule of reinsurance contracts with risk-limiting features as of and for the year ended December 31, 2020 are presented for purposes of additional analysis and are not a required part of the 2020 statutory basis financial statements. These schedules are the responsibility of the Company's management and were derived from and relate directly to the underlying accounting and other records used to prepare the statutory basis financial statements. Such schedules have been subjected to the auditing procedures applied in our audit of the 2020 statutory basis financial statements and certain additional procedures, including comparing and reconciling such schedules directly to the underlying accounting and other records used to prepare the statutory basis financial statements or to the statutory basis financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, such schedules are fairly stated in all material respects in relation to the 2020 statutory basis financial statements as a whole.

Restriction on Use

Our report is intended solely for the information and use of the Audit Committee and the management of UnitedHealthcare of Louisiana, Inc. and for filing with state insurance departments to whose jurisdiction the Company is subject and is not intended to be and should not be used by anyone other than these specified parties.

A handwritten signature in black ink that reads "Deloitte + Touche LLP". The signature is written in a cursive, flowing style.

April 16, 2021

UNITEDHEALTHCARE OF LOUISIANA, INC.

STATUTORY BASIS STATEMENTS OF ADMITTED ASSETS, LIABILITIES, AND CAPITAL AND SURPLUS AS OF DECEMBER 31, 2020 AND 2019

	2020	2019
ADMITTED ASSETS		
CASH AND INVESTED ASSETS:		
Bonds	\$ 241,426,031	\$ 234,814,073
Cash of \$52,653 and \$45,057, and cash equivalents of \$262,697,267 and \$177,592,989, in 2020 and 2019, respectively	262,749,920	177,638,046
Other invested assets	<u>2,434,863</u>	<u>-</u>
Subtotal cash and invested assets	<u>506,610,814</u>	<u>412,452,119</u>
OTHER ASSETS:		
Investment income due and accrued	2,093,990	2,304,540
Premiums and considerations	208,368,365	195,005,855
Amounts receivable relating to uninsured plans	175,058	217,734
Net deferred tax asset	13,860,345	13,293,810
Health care receivables	<u>1,724,492</u>	<u>2,814,050</u>
Subtotal other assets	<u>226,222,250</u>	<u>213,635,989</u>
TOTAL ADMITTED ASSETS	<u>\$ 732,833,064</u>	<u>\$ 626,088,108</u>
LIABILITIES AND CAPITAL AND SURPLUS		
LIABILITIES:		
Claims unpaid	\$ 329,472,987	\$ 305,410,683
Accrued medical incentive pool and bonus amounts	2,391,012	10,916,024
Unpaid claims adjustment expenses	1,427,483	1,111,430
Aggregate health policy reserves	65,812,140	59,629,719
Aggregate health claim reserves	3,257,501	2,544,795
Premiums received in advance	320,182	141,813
General expenses due or accrued	58,821,565	45,408,243
Current federal income tax payable	751,100	4,258,754
Ceded reinsurance premiums payable	175,349	162,450
Remittances and items not allocated	68	438
Amounts due to parent, subsidiaries, and affiliates, net	5,032,641	11,436,936
Liability for amounts held under uninsured plans	<u>58,572</u>	<u>52,913</u>
Total liabilities	<u>467,520,600</u>	<u>441,074,198</u>
CAPITAL AND SURPLUS:		
Section 9010 ACA subsequent fee year assessment	-	43,016,618
Common capital stock, \$2 par value — 1,000,000 shares authorized; 900,000 shares issued and outstanding	1,800,000	1,800,000
Gross paid-in and contributed surplus	67,138,440	67,138,440
Unassigned surplus	<u>196,374,024</u>	<u>73,058,852</u>
Total capital and surplus	<u>265,312,464</u>	<u>185,013,910</u>
TOTAL LIABILITIES AND CAPITAL AND SURPLUS	<u>\$ 732,833,064</u>	<u>\$ 626,088,108</u>

See notes to statutory basis financial statements.

UNITEDHEALTHCARE OF LOUISIANA, INC.

STATUTORY BASIS STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	2020	2019
REVENUES:		
Net premium income	\$ 2,637,682,936	\$ 2,342,968,696
Change in reserve for rate credits	<u>(34,507,580)</u>	<u>4,385,743</u>
Total revenues	<u>2,603,175,356</u>	<u>2,347,354,439</u>
UNDERWRITING DEDUCTIONS:		
Hospital and medical:		
Hospital/medical benefits	1,263,294,322	1,193,708,752
Other professional services	18,070,327	22,498,626
Prescription drugs	527,019,911	411,228,861
Full Medicaid pricing pass through	336,061,399	369,529,001
Incentive pool, withhold adjustments, and bonus amounts	16,639,707	15,978,309
Net reinsurance incurred	<u>968,932</u>	<u>657,055</u>
Total hospital and medical	2,162,054,598	2,013,600,604
Claims adjustment expenses	82,594,580	95,129,543
General administrative expenses	249,391,327	210,859,871
Decrease in reserves for accident and health contracts	<u>(23,233,000)</u>	<u>(20,432,000)</u>
Total underwriting deductions	<u>2,470,807,505</u>	<u>2,299,158,018</u>
NET UNDERWRITING GAIN	<u>132,367,851</u>	<u>48,196,421</u>
NET INVESTMENT GAINS:		
Net investment income earned	6,363,631	8,516,496
Net realized capital losses less capital benefit of \$61,394 and \$15,440 in 2020 and 2019, respectively	<u>(230,960)</u>	<u>(100,047)</u>
Total net investment gains	<u>6,132,671</u>	<u>8,416,449</u>
NET LOSS FROM AGENTS' OR PREMIUM BALANCES CHARGED OFF	<u>(280,259)</u>	<u>(63,492)</u>
NET INCOME BEFORE FEDERAL INCOME TAXES	138,220,263	56,549,378
FEDERAL INCOME TAXES INCURRED	<u>33,166,495</u>	<u>7,633,194</u>
NET INCOME	<u>\$ 105,053,768</u>	<u>\$ 48,916,184</u>

See notes to statutory basis financial statements.

UNITEDHEALTHCARE OF LOUISIANA, INC.

STATUTORY BASIS STATEMENTS OF CHANGES IN CAPITAL AND SURPLUS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	Section 9010 ACA Subsequent Fee Year Assessment	Common Capital Stock Shares	Common Capital Stock Amount	Gross Paid-In and Contributed Surplus	Unassigned Surplus	Total Capital and Surplus
BALANCE — January 1, 2019	\$ -	900,000	\$ 1,800,000	\$ 67,138,440	\$ 81,309,353	\$ 150,247,793
Net income	-	-	-	-	48,916,184	48,916,184
Change in net unrealized capital losses on investments less capital gains benefit of (\$71)	-	-	-	-	267	267
Change in net deferred income taxes	-	-	-	-	(1,297,569)	(1,297,569)
Change in nonadmitted assets	-	-	-	-	(12,852,765)	(12,852,765)
Section 9010 ACA subsequent fee year assessment	<u>43,016,618</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>(43,016,618)</u>	<u>-</u>
BALANCE — December 31, 2019	43,016,618	900,000	1,800,000	67,138,440	73,058,852	185,013,910
Net income	-	-	-	-	105,053,768	105,053,768
Change in net unrealized capital losses on investments less capital gains benefit of (\$58)	-	-	-	-	(218)	(218)
Change in net deferred income taxes	-	-	-	-	566,477	566,477
Change in nonadmitted assets	-	-	-	-	(25,321,473)	(25,321,473)
Section 9010 ACA subsequent fee year assessment	<u>(43,016,618)</u>	<u>-</u>	<u>-</u>	<u>-</u>	<u>43,016,618</u>	<u>-</u>
BALANCE — December 31, 2020	<u>\$ -</u>	<u>900,000</u>	<u>\$ 1,800,000</u>	<u>\$ 67,138,440</u>	<u>\$ 196,374,024</u>	<u>\$ 265,312,464</u>

See notes to statutory basis financial statements.

UNITEDHEALTHCARE OF LOUISIANA, INC.

STATUTORY BASIS STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

	2020	2019
CASH FLOWS FROM OPERATIONS:		
Premiums collected, net of reinsurance	\$ 2,619,433,941	\$ 2,335,729,020
Net investment income	8,665,199	10,640,897
Benefit and loss related payments	(2,170,051,766)	(1,950,089,443)
Commissions and other expenses paid	(318,483,805)	(316,401,361)
Federal income taxes paid, net	<u>(36,612,755)</u>	<u>(22,083,065)</u>
Net cash provided by operations	<u>102,950,814</u>	<u>57,796,048</u>
CASH FLOWS FROM INVESTMENTS:		
Proceeds from investments:		
Bonds sold or matured	27,276,272	77,009,943
Miscellaneous proceeds	<u>(3,310)</u>	<u>338</u>
Total investment proceeds	<u>27,272,962</u>	<u>77,010,281</u>
Cost of investments acquired:		
Bonds	(36,271,591)	(82,083,644)
Other invested assets	<u>(2,436,492)</u>	<u>-</u>
Total cost of investments acquired	<u>(38,708,083)</u>	<u>(82,083,644)</u>
Net cash used in investments	<u>(11,435,121)</u>	<u>(5,073,363)</u>
CASH FLOWS FROM FINANCING AND MISCELLANEOUS ACTIVITIES:		
Cash used in net transfers to affiliates	(6,404,295)	(118,618)
Other cash provided	<u>476</u>	<u>1,589</u>
Net cash used in financing and miscellaneous activities	<u>(6,403,819)</u>	<u>(117,029)</u>
RECONCILIATION OF CASH AND CASH EQUIVALENTS:		
NET CHANGE IN CASH AND CASH EQUIVALENTS	85,111,874	52,605,656
CASH AND CASH EQUIVALENTS — Beginning of year	<u>177,638,046</u>	<u>125,032,390</u>
CASH AND CASH EQUIVALENTS — End of year	<u>\$ 262,749,920</u>	<u>\$ 177,638,046</u>

See notes to statutory basis financial statements.

UNITEDHEALTHCARE OF LOUISIANA, INC.

NOTES TO STATUTORY BASIS FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN

Organization and Operation

UnitedHealthcare of Louisiana, Inc. (the "Company"), licensed as a health maintenance organization ("HMO"), offers its enrollees a variety of managed care programs and products through contractual arrangements with health care providers. The Company is a wholly owned subsidiary of UnitedHealthcare, Inc. ("UHC"). UHC is a wholly owned subsidiary of United HealthCare Services, Inc. ("UHS"), a management corporation that provides services to the Company under the terms of a management agreement (the "Agreement"). UHS is a wholly owned subsidiary of UnitedHealth Group Incorporated ("UnitedHealth Group"). UnitedHealth Group is a publicly held company trading on the New York Stock Exchange.

The Company was incorporated on April 9, 1986, as an HMO and operations commenced in November 1986. The Company is certified as an HMO, by the Louisiana Department of Insurance ("LADOI"). The Company has entered into contracts with physicians, hospitals, and other health care provider organizations to deliver health care services for all enrollees.

The Company offers comprehensive commercial products to employer groups. Each contract outlines the coverage provided and renewal provisions.

The Company served as a plan sponsor offering Medicare Parts A & B, along with Medicare Part D prescription drug insurance coverage (collectively "Medicare program") under a contract with the Centers for Medicare and Medicaid Services ("CMS"). The Company receives seven different payment elements either during the year or at final settlement in the subsequent year: CMS premium, member premium, CMS low-income premium subsidy, CMS catastrophic reinsurance subsidy, CMS low-income member cost-sharing subsidy, CMS risk share, and the CMS coverage gap discount program ("CGDP"). The applicable payment elements are received either during the year or at settlement in the subsequent year. Each component of the Medicare program is further defined throughout Note 1. Effective January 1, 2020, the Company has elected not to participate as a sponsor of the Medicare program in the State of Louisiana.

The Company has a contract with the State of Louisiana, Louisiana Department of Health ("LDH"), to provide health care services to Healthy Louisiana (a program for uninsured adults and children) eligible beneficiaries in Louisiana. The current contract is effective through December 31, 2021.

A. Accounting Practices

The statutory basis financial statements of the Company are presented on the basis of accounting practices prescribed or permitted by the LADOI.

The LADOI recognizes only statutory accounting practices, prescribed or permitted by the State of Louisiana, for determining and reporting the financial condition and results of operations of an HMO, for determining its solvency under Louisiana Insurance Law. The state prescribes the use of the National Association of Insurance Commissioners' ("NAIC") Accounting Practices and Procedures manual ("NAIC SAP") in effect for the accounting periods covered in the statutory basis financial statements.

No significant differences exist between the practices prescribed or permitted by the State of Louisiana and the NAIC SAP which materially affect the statutory basis net income and capital and surplus, as illustrated in the table below:

	SSAP #	AFS Line Desc	December 31, 2020	December 31, 2019
Net Income				
(1) Company state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	\$ 105,053,768	\$ 48,916,184
(2) State prescribed practices that are an increase/(decrease) from NAIC SAP: Not Applicable			-	-
(3) State permitted practices that are an increase/(decrease) from NAIC SAP: Not Applicable			-	-
(4) NAIC SAP (1 - 2 - 3 = 4)	XXX	XXX	<u>\$ 105,053,768</u>	<u>\$ 48,916,184</u>
Capital and Surplus				
(5) Company state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	\$ 265,312,464	\$ 185,013,910
(6) State prescribed practices that are an increase/(decrease) from NAIC SAP: Not Applicable			-	-
(7) State permitted practices that are an increase/(decrease) from NAIC SAP: Not Applicable			-	-
(8) NAIC SAP (5 - 6 - 7 = 8)	XXX	XXX	<u>\$ 265,312,464</u>	<u>\$ 185,013,910</u>

B. Use of Estimates in the Preparation of the Statutory Basis Financial Statements

The preparation of these statutory basis financial statements in conformity with the NAIC Annual Statement Instructions and the NAIC SAP include certain amounts that are based on the Company's estimates and judgments. These estimates require the Company to apply complex assumptions and judgments, often because the Company must make estimates about the effects of matters that are inherently uncertain and will change in subsequent periods. The most significant estimates relate to hospital and medical benefits, claims unpaid, aggregate health policy reserves (including medical loss ratio rebates and premium deficiency reserves ("PDR")), aggregate health claim reserves, and risk adjustment estimates. The Company adjusts these estimates each period as more current information becomes available. The impact of any changes in estimates is included in the determination of net income in the period in which the estimate is adjusted.

C. Accounting Policy

Basis of Presentation — The Company prepares its statutory basis financial statements on the basis of accounting practices prescribed or permitted by the LADOI. These statutory practices differ from accounting principles generally accepted in the United States of America ("GAAP").

Accounting policy disclosures that are required by the NAIC Annual Statement instructions are as follows:

- (1–2) Bonds are stated at book/adjusted carrying value if they meet NAIC designation of one or two and stated at the lower of book/adjusted carrying value or fair value if they meet an NAIC designation of three or higher. The Company does not have any mandatory convertible securities or Securities Valuation Office of the NAIC ("SVO") identified funds

(i.e.: exchange traded funds or bond mutual funds) in its bond portfolio. Amortization of bond premium or accretion of discount is calculated using the constant-yield interest method. Bonds are valued and reported using market prices published by the SVO in accordance with the NAIC Valuation of Securities manual prepared by the SVO or an external pricing service;

- (3–4) The Company holds no common or preferred stock;
- (5) The Company holds no mortgage loans on real estate;
- (6) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors. The Company's investment policy limits investments in nonagency residential mortgage-backed securities, including home equity and sub-prime mortgages, to 10% of total cash and invested assets. Total combined investments in mortgage-backed securities and asset-backed securities cannot exceed more than 30% of total cash and invested assets;
- (7) The Company holds no investments in subsidiaries, controlled, or affiliated entities;
- (8) The Company has no investment interests with respect to joint ventures, partnerships, or limited liability companies;
- (9) The Company holds no derivatives;
- (10) PDR (inclusive of conversion reserves) and the related expenses are recognized when it is probable that expected future health care expenses, claims adjustment expenses ("CAE"), direct administration costs, and an allocation of indirect administration costs under a group of existing contracts will exceed anticipated future premiums and reinsurance recoveries considered over the remaining lives of the contracts, and are recorded as aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Indirect administration costs arise from activities that are not specifically identifiable to a specific group of existing contracts, and therefore, those costs are fully allocated among the various contract groupings. The allocation of indirect administration costs to each contract grouping is made proportionately to the expected margins remaining in the premiums after future health care expenses, CAE and direct administration costs are considered. The data and assumptions underlying such estimates and the resulting reserves are periodically updated, and any adjustments are reflected as a decrease in reserves for accident and health contracts in the statutory basis statements of operations in the period in which the change in estimate is identified. The Company does anticipate investment income as a factor in the PDR calculation (see Note 30);
- (11) CAE are those costs expected to be incurred in connection with the adjustment and recording of accident and health claims. Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to its affiliate, UHS, in exchange for administrative and management services. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between CAE and general administrative expenses ("GAE") to be reported in the statutory basis statements of operations. It is the responsibility of UHS to pay CAE in the event the Company ceases operations. The Company has recorded an estimate of unpaid CAE associated with incurred but unpaid claims, which is included in unpaid CAE in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Management believes the amount of the liability for unpaid CAE as of December 31, 2020 is adequate to cover

the Company's cost for the adjustment and recording of unpaid claims; however, actual expenses may differ from those established estimates. Adjustments to the estimates for unpaid CAE are reflected in operating results in the period in which the change in estimate is identified;

- (12) The Company does not carry any fixed assets in the statutory basis financial statements;
- (13) Health care receivables consist of pharmacy rebates receivable estimated based on the most currently available data from the Company's claims processing systems and from data provided by the Company's affiliated pharmaceutical benefit manager, OptumRx, Inc. ("OptumRx"). Health care receivables also include receivables for amounts due to the Company for claim overpayments to providers, hospitals and other health care organizations. Health care receivables are considered nonadmitted assets under the NAIC SAP if they do not meet admissibility requirements. Accordingly, the Company has excluded receivables that do not meet the admissibility criteria from the statutory basis statements of admitted assets, liabilities, and capital and surplus (see Note 28).

The Company has also deemed the following to be significant accounting policies and/or differences between statutory practices and GAAP:

ASSETS

Cash and Invested Assets

- The Company holds no short-term investments;
- Bonds include U.S. government and agency securities, state and agency municipal securities, city and county municipal securities, and corporate debt securities, with a maturity of greater than one year at the time of purchase;
- Certain debt investments categorized as available-for-sale or held-to-maturity under GAAP are presented at the lower of book/adjusted carrying value or fair value in accordance with the NAIC designations in the statutory basis financial statements, whereas under GAAP, these investments are shown at fair value or book/adjusted carrying value, respectively;
- Cash and cash equivalents in the statutory basis financial statements represent cash balances and investments with original maturities of one year or less from the time of acquisition, whereas under GAAP, the corresponding caption of cash, cash equivalents, and short-term investments includes cash balances and investments that will mature in one year or less from the balance sheet date;
- Cash represents cash held by the Company in operating accounts. Claims and other payments are made from the operating accounts daily;
- Outstanding checks are required to be netted against cash balances or presented as cash overdrafts if in excess of cash balances in the statutory basis statements of admitted assets, liabilities, and capital and surplus as opposed to being presented as other liabilities under GAAP;
- Cash equivalents include money-market funds. Cash equivalents have original maturity dates of three months or less from the date of acquisition. Money-market funds are reported at fair value or net asset value ("NAV") as a practical expedient;
- Realized capital gains and losses on sales of investments are calculated based upon specific identification of the investments sold. These gains and losses are reported as net realized capital losses less capital gains benefit ("net realized capital gains (losses) less taxes") in the statutory basis statements of operations;

- The Company continually monitors the difference between amortized cost and estimated fair value of its investments. If any of the Company's investments experience a decline in value that the Company has determined is other-than-temporary, or if the Company has determined it will sell a security that is in an impaired status, the Company will record a realized loss in net realized capital gains (losses) less taxes in the statutory basis statements of operations. The new cost basis is not changed for subsequent recoveries in fair value. The prospective adjustment method is utilized for loan-backed securities for periods subsequent to the loss recognition. The Company recognized an other-than-temporary impairment ("OTTI") of \$555,076 and \$0 for the years ended December 31, 2020 and 2019, respectively;
- The NAIC SAP requires the following captions to be taken into consideration in the reconciliation of the statutory basis statements of cash flows: cash, including cash overdrafts, cash equivalents, and short-term investments, which can include restricted cash reserves, with original maturities of one year or less from the time of acquisition, whereas under GAAP, pursuant to Accounting Standards Update 2016-18, *Statement of Cash Flows, Restricted Cash*, the statements of cash flows reconcile the corresponding captions of cash, cash equivalents and restricted cash with maturities of three months or less. Short-term investments with a final maturity of one year or less from the balance sheet date are not included in the reconciliation of GAAP cash flows. In addition, there are classification differences within the presentation of the cash flow categories between GAAP and NAIC SAP. The statutory basis statements of cash flows are prepared in accordance with the NAIC Annual Statement Instructions.
- **Other Invested Assets** — Other invested assets include low-income housing tax credit ("LIHTC") investments which are stated at book/adjusted carrying value, which approximates fair value in the statutory basis statements of admitted assets, liabilities and capital and surplus.

Other Assets

- **Investment Income Due and Accrued** — Investment income earned and due as of the reporting date, in addition to investment income earned but not paid or collected until subsequent periods, is reported as investment income due and accrued in the statutory basis statements of admitted assets, liabilities, and capital and surplus. The Company evaluates the collectability of the amounts due and accrued and amounts determined to be uncollectible are written off in the period in which the determination is made. In addition, the remaining balance is assessed for admissibility and any balance greater than 90 days past due is considered a nonadmitted asset.
- **Premiums and Considerations** — The Company reports uncollected premium balances from its insured groups, CMS, and state Medicaid agency as premiums and considerations in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Uncollected premium balances that are over 90 days past due, with the exception of amounts due from government insured plans, are considered nonadmitted assets. In addition to those balances, current balances are also considered nonadmitted if the corresponding balance greater than 90 days past due is deemed more than inconsequential. Premiums and considerations also include the following (see Note 24):
 - a) commercial risk adjustment receivables as defined in Section 1343 of the Affordable Care Act ("ACA"). Premium adjustments are based upon the risk scores (health status) of enrollees participating in risk adjustment covered plans, rather than the actual loss experience of the insured. The risk adjustments and distributions are calculated using a high-cost risk pool which adds a reinsurance-like element to this program. A risk adjustment receivable is recorded when the Company estimates its

average actuarial risk score for policies included in this program is greater than the average actuarial risk scores in that market and state risk pool;

- b) CMS risk corridor receivables for which adjustments are based on whether the ultimate per member per month ("PMPM") benefit costs of any Medicare Plan varies more than 5% above the level estimated in the original bid submitted by the Company and approved by CMS;
- c) CMS risk adjustment receivables for the Medicare Plans. The risk adjustment model apportions premiums paid to all health plans according to the health severity and certain demographic factors of its enrollees. The CMS risk adjustment model pays more for members whose medical history indicates they have certain medical conditions. Under this risk adjustment methodology, CMS calculates the risk-adjusted premium payment using diagnosis data from hospital inpatient, hospital outpatient, and physician treatment settings. The Company and health care providers collect, capture, and submit the necessary and available diagnosis data to CMS within prescribed deadlines. The Company estimates risk adjustment revenues based upon the diagnosis data submitted and expected to be submitted to CMS. The Company recognizes such changes when the amounts become determinable and supportable and collectability is reasonably assured;
- d) premium withhold receivables from LDH which are calculated as a percentage of the capitation rate based on the Company's estimate of performance metrics that have been met as of the financial statement date; and
- e) Hepatitis C risk corridor receivables from LDH for which adjustments are based on whether the Company's actual loss ratios are in excess of minimal loss ratio requirements based on plan variances from the original estimated capitation rates.

Premium adjustments for the CMS and Medicaid risk corridor programs are accounted for as premium adjustments subject to retrospectively rated features. Premium adjustments for the commercial ACA Section 1343 risk adjustment, CMS risk adjustment, and Medicaid performance program are accounted for as premium adjustments subject to redetermination.

- **Amounts Receivable Relating to Uninsured Plans** — The Company reports amounts due to the Company from CMS for the administrative activities it performs for which it has no insurance risk as amounts receivable relating to uninsured plans (see Note 18). Amounts receivable relating to uninsured plans include the following:
 - a) costs incurred in excess of the cost reimbursement under the Medicare Plans for the catastrophic reinsurance subsidy and the low-income member cost-sharing subsidy for the individual members. The Company is fully reimbursed by CMS for costs incurred for these contract elements, and accordingly, there is no insurance risk to the Company. Subsidies for individual members are received monthly and are not reflected as net premium income, but rather are accounted for as deposits. If the Company incurs costs in excess of these subsidies, a corresponding receivable is recorded; and
 - b) the ACA mandates consumer discounts of 70% on brand name prescription drugs for Part D plan participants in the coverage gap. As part of the CGDP, the Company records a receivable from the pharmaceutical manufacturers for reimbursement of the discounts. The Company solely administers the application of these funds and has no insurance risk.

- **Net Deferred Tax Asset** — The NAIC SAP provides for an amount to be recorded for deferred taxes on temporary differences between the financial reporting and tax bases of assets, subject to a valuation allowance and admissibility limitations on deferred tax assets (see Note 9). In addition, under the NAIC SAP, the change in deferred tax assets is recorded directly to unassigned surplus in the statutory basis financial statements, whereas under GAAP, the change in deferred tax assets is recorded as a component of the income tax provision within the income statement and is based on the ultimate recoverability of the deferred tax assets. Based on the admissibility criteria under the NAIC SAP, any deferred tax assets determined to be nonadmitted are charged directly to surplus and excluded from the statutory basis financial statements, whereas under GAAP, such assets are included in the balance sheet.

LIABILITIES

- **Claims Unpaid and Aggregate Health Claim Reserves** — Claims unpaid and aggregate health claim reserves include claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

The estimates for incurred but not yet reported claims are developed using an actuarial process that is consistently applied, centrally controlled, and automated. The actuarial models consider factors such as historical submission and payment data, cost trends, customer and product mix, seasonality, utilization of health care services, contracted service rates, and other relevant factors. The Company estimates such liabilities for physician, hospital, and other medical cost disputes based upon an analysis of potential outcomes, assuming a combination of litigation and settlement strategies. These estimates may change as actuarial methods change or as underlying facts upon which estimates are based change. The Company did not change actuarial methods during 2020 and 2019. Management believes the amount of claims unpaid and aggregate health claim reserves is a best estimate of the Company's liability for unpaid claims and aggregate health claim reserves as of December 31, 2020; however, actual payments may differ from those established estimates.

The reserves ceded to reinsurers for claims unpaid and aggregate health claim reserves have been reported as reductions of the related reserves rather than as assets, which would be required under GAAP.

The Company contracts with hospitals, physicians, and other providers of health care under capitated or discounted fee for service arrangements, including a hospital per diem to provide medical care services to enrollees. Some of these contracts are with related parties (see Note 10). Capitated providers are at risk for the cost of medical care services provided to the Company's enrollees; however, the Company is ultimately responsible for the provision of services to its enrollees should the capitated provider be unable to provide the contracted services.

The Company has a contract with the LDH in which the Company processes Full Medicaid Pricing ("FMP") payments to specified providers where the FMP has agreements. The Company records both the amounts collected from the LDH and the amounts disbursed to providers, excluding FMP related premium tax, as net premium income and hospital and medical expense, respectively, in the statutory basis statements of operations. Unsettled FMP payments owed to providers, net of premium tax, of \$151,676,494 and \$167,688,518 is included in claims unpaid as of December 31, 2020 and 2019, respectively, in the statutory basis statements of admitted assets, liabilities and capital and surplus.

- **Accrued Medical Incentive Pool and Bonus Amounts** — The Company has agreements with certain independent physicians and physician network organizations that provide for the establishment of a fund into which the Company places monthly premiums payable for members assigned to the physician. The Company manages the disbursement of funds from this account as well as reviews the utilization of nonprimary care medical services of members assigned to the physicians. Any surpluses in the fund are shared by the Company and the physician based upon predetermined risk-sharing percentage and the liability is included in accrued medical incentive pool and bonus amounts in the statutory basis statements of admitted assets, liabilities, and capital and surplus. The Company also has incentive and bonus arrangements with providers that are based on quality, utilization, and/or various health outcome measures. The estimated amount due to providers that meet the established metrics is included in accrued medical incentive pool and bonus amounts in the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- **Aggregate Health Policy Reserves** — Aggregate health policy reserves includes:
 - a) commercial risk adjustment payables as defined in Section 1343 of the ACA. Premium adjustments are based upon the risk scores (health status) of enrollees participating in risk adjustment covered plans, rather than the actual loss experience of the insured. The risk adjustments and distributions are calculated using a high-cost risk pool which adds a reinsurance-like element to this program. A risk adjustment payable is recorded when the Company estimates its average actuarial risk score for policies included in this program is less than the average actuarial risk scores in that market and state risk pool. The data used by CMS to determine the risk adjustment amount is subject to risk adjustment data validation audits along with the true-up to the final CMS report, which may result in a material change to arrive at the final risk adjustment amount from the initial risk adjustment estimate recorded (see Note 24);
 - b) CMS risk adjustment payables for the Medicare Plans. The risk adjustment model apportions premiums paid to all health plans according to the health severity and certain demographic factors of its Medicare Plans enrollees. The CMS risk adjustment model pays more for members whose medical history indicates they have certain medical conditions. Under this risk adjustment methodology, CMS calculates the risk-adjusted premium payment using diagnosis data from hospital inpatient, hospital outpatient, and physician treatment settings. The Company and health care providers collect, capture, and submit the necessary and available diagnosis data to CMS within prescribed deadlines. If diagnosis data submitted to CMS needs to be corrected or deleted, the revised diagnosis data can be re-submitted. The Company estimates reductions to risk adjustment revenues and corresponding change in CMS risk adjustment payables based upon the diagnosis data submitted and expected to be submitted to CMS. The Company recognizes such changes when the amounts become determinable and supportable (see Note 24);
 - c) estimated rebates payable on the comprehensive commercial, Medicaid and Medicare Plans, if the medical loss ratios on these fully insured products, as calculated under the definitions of the ACA and/or State statutes and implementing regulations, fall below certain targets. The Company is required to rebate the ratable portions of the premiums annually (see Note 24);
 - d) risk corridor payables due to LDH for which adjustments are based on whether the Company incurs benefit costs that are less than 98% of the target amount for the products subject to the corridor; (see Note 24); and

e) the estimated amount for PDR (see Note 30).

- **Premiums Received in Advance** — Premiums received in full for the policies processed during the current period, but prior to the commencement of the service period, are recorded as premiums received in advance in the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- **General Expenses Due or Accrued** — General expenses that are due as of the reporting date in addition to general expenses that have been incurred but are not due until a subsequent period are reported as general expenses due or accrued in the statutory basis statements of admitted assets, liabilities, and capital and surplus. General expenses due or accrued also include the amounts for unpaid assessments, premium taxes, and the unpaid portion of the contributions required under the ACA risk adjustment program (see Note 24).
- **Current Federal Income Tax Payable** — The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses, the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal income tax return of UnitedHealth Group. A liability for federal income taxes payable is recognized when its allocated intercompany estimated payments are less than its actual calculated obligation based on the Company's stand-alone federal income tax return (see Note 9).
- **Remittances and Items Not Allocated** — Remittances and items not allocated generally represent monies received from policyholders for monthly premium billings or providers that have not been specifically identified or applied prior to year-end. The majority is from monies received in the lockbox account on the last day of the year.
- **Amounts Due to Parent, Subsidiaries, and Affiliates, Net** — In the normal course of business, the Company has various transactions with related parties (see Note 10). The Company reports any unsettled amounts owed as amounts payable to parent, subsidiaries, and affiliates, net, in the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- **Liability for Amounts Held Under Uninsured Plans** — Liability for amounts held under uninsured plans represents amounts due from the Company to CMS for the administrative activities it performs for which it has no insurance risk (see Note 18). Liabilities for amounts held under uninsured plans includes the ACA mandates consumer discounts of 70% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are pre-funded for the individual members by CMS and a liability for the amount subject to recoupment is recorded. The Company solely administers the application of these funds and has no insurance risk.

CAPITAL AND SURPLUS AND MINIMUM STATUTORY REQUIREMENTS

- **Nonadmitted Assets** — Certain assets, including certain aged premium receivables, certain health care receivables and prepaid expenses, are considered nonadmitted assets under the NAIC SAP and are excluded from the statutory basis statements of admitted assets, liabilities, and capital and surplus and charged directly to unassigned surplus. Under GAAP, such assets are included in the balance sheet.
- **Restricted Cash Reserves** — The Company held regulatory deposits in the amount of \$1,000,000 as of December 31, 2020 and 2019, respectively, in compliance with the State of Louisiana requirements for qualification purposes as a domestic insurer. These restricted

cash reserves consist principally of industrial and miscellaneous bonds and are stated at book/adjusted carrying value, which approximates fair value. These restricted deposits are included in bonds in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Interest earned on these deposits accrues to the Company.

- **Minimum Capital and Surplus** — Under the laws of the State of Louisiana, the LADOI requires the Company to maintain a minimum capital and surplus equal to \$3,000,000.

Risk-based capital (“RBC”) is a regulatory tool for measuring the minimum amount of capital appropriate for a managed care organization to support its overall business operations in consideration of its size and risk profile. The LADOI requires the Company to maintain minimum capital and surplus equal to the greater of the state statute as outlined above, or the company action level as calculated by the RBC formula, or the level needed to avoid action pursuant to the trend test in the RBC formula.

The Company has \$265,312,464 and \$185,013,910 in total statutory basis capital and surplus as of December 31, 2020 and 2019, respectively, which is in compliance with the required amounts where it is licensed to do business.

- **Section 9010 ACA Subsequent Fee Year Assessment** — The Company is subject to the Section 9010 ACA subsequent fee year assessment. Under the NAIC SAP, as of December, 31, 2019, an amount equal to the estimated subsequent year fee was apportioned out of unassigned surplus and reported as Section 9010 ACA subsequent fee year assessment, in the statutory basis statements of admitted assets, liabilities, and capital and surplus, whereas under GAAP, no such special surplus designation is required. In accordance with the 2021 Health Insurer Fee (“HIF”) repeal, no HIF will be payable in 2021 or thereafter, therefore no amounts will be apportioned out of unassigned surplus after December 31, 2019.

STATEMENTS OF OPERATIONS

- **Net Premium Income and Change in Reserve for Rate Credits** — Revenues consist of net premium income that is recognized in the period in which enrollees are entitled to receive health care services. Net premium income is shown net of reinsurance premiums paid and reinsurance premiums incurred but not paid in the statutory basis statements of operations. The corresponding change in unearned premium from year to year is reflected as a change in reserve for rate credits in the statutory basis statements of operations. Under GAAP, the change in unearned premium from year to year is reported through premium income.

Comprehensive commercial health plans with medical loss ratios on fully insured products, as calculated under the definitions in the ACA (see Note 14) and implementing regulations, that fall below certain targets are required to rebate ratable portions of premiums annually. The Company classifies its estimated rebates as change in reserve for rate credits in the statutory basis statements of operations.

Pursuant to Section 1342 and Section 1343 of the ACA, the Company records premium adjustments for changes to the commercial risk corridor and commercial risk adjustment balances which are reflected in change in reserve for rate credits and net premium income, respectively, in the statutory basis statements of operations (see Note 24).

Net premium income includes premiums under the Medicare Plans which includes CMS premiums, including amounts pursuant to the CMS risk adjustment program, member premiums, and the CMS low-income premium subsidy for the Company’s insurance risk

coverage. Net premium is recognized ratably over the period in which eligible individuals are entitled to receive health care services and prescription drug benefits.

Company also records estimates related to the CMS Medicare risk corridor program. Changes to these estimates are reflected as change in reserve for rate credits in the statutory basis statements of operations.

The Company's Medicare Plans are subject to medical loss ratio requirements under the ACA. Plans with medical loss ratios that fall below certain targets are required to rebate ratable portions of premiums annually. The Company classifies its estimated rebates as change in reserve for rate credits in the statutory basis statements of operations.

Net premium income also includes amounts paid by state and federal governments on a per member basis in exchange for the provision and administration of medical benefits under the Medicaid Program. Premiums are contractual and are recognized in the coverage period in which members are entitled to receive services, except in the case of maternity payments. Maternity income is billed on contractual rates and recognized as income as each birth case is identified by the Company. Included in net premium income are capitated payments, home nursing risk-sharing payments, high-dollar risk pool payments, and maternity payments. The majority of net premium income recorded is based on capitated rates, which are monthly premiums paid for each member enrolled. Home nursing risk-sharing income is payable based upon the number of members that qualify for such reimbursement.

The Medicaid plan is subject to experience rebates, risk adjustments, and performance guarantees based on various utilization measures. The Company has reported its estimated risk adjustments and experience rebates as a component of net premium income and change in reserve for rate credits, respectively, in the statutory basis statements of operations.

- **Full Medicaid Pricing Pass Through Program** — The LDH and the Company entered into a contract in which the Company processes FMP payments to specified providers where the FMP has agreements. Once received from the LDH, the Company disburses funds from an allocated pool to hospitals, physician groups, and ambulance groups, less any premium taxes. The funds that have been received cannot be directly linked to a specific claim. Additionally, the Company has no obligation to pay the specified providers until funds have been received. The amounts collected, net of tax, are included in net premium income in the statutory basis statements of operations whereas under GAAP, this program is presented on a net basis as general administrative expenses. FMP receipts of \$345,728,446 and \$369,529,001 were recorded to net premium income as of December 31, 2020 and 2019 respectively.
- **Total Hospital and Medical Expenses** — Total hospital and medical expenses include claims paid, claims processed but not yet paid, estimates for claims received but not yet processed, estimates for the costs of health care services enrollees have received but for which claims have not yet been submitted, and payments and liabilities for physician, hospital, and other medical costs disputes.

Total hospital and medical expenses also include amounts incurred for incentive pool, withhold adjustments, and bonus amounts that are based on the underlying contractual provisions with the respective providers. In addition, adjustments to claims unpaid estimates and aggregate health claim reserves are reflected in the period once the change in estimate is identified and included in total hospital and medical expenses in the statutory basis statements of operations.

- **General Administrative Expenses** — Pursuant to the terms of the Agreement (see Note 10), the Company pays a management fee to UHS in exchange for administrative and management services. Costs for items not included within the scope of the Agreement are directly expensed as incurred. Premium taxes are also a component of GAE. A detailed review of the administrative expenses of the Company and UHS is performed to determine the allocation between CAE and GAE to be reported in the statutory basis statements of operations.

The Company is subject to an annual fee under Section 9010 of the ACA. A health insurance entity's annual fee becomes payable once the entity provides health insurance for any U.S. health risk during the calendar year, which is nondeductible for tax purposes (see Note 22). Under the NAIC SAP, the entire amount of the estimated annual fee expense is recognized on January 1 of the fee year in GAE in the statutory basis statements of operations, whereas under GAAP, a deferred asset is created on January 1 of the fee year which is amortized to expense on a straight-line basis throughout the year.

- **Net Investment Income Earned** — Net investment income earned includes investment income collected during the period, as well as the change in investment income due and accrued on the Company's holdings. Amortization of premium or discount on bonds and certain external investment management costs are also included in net investment income earned (see Note 7).
- **Federal Income Taxes Incurred** — The provision for federal income taxes incurred calculated based on applying the statutory federal income tax rate of 21% to net income before federal income taxes and net realized capital losses subject to certain adjustments (see Note 9).
- **Comprehensive Income** — Comprehensive income and its components are not separately presented in the statutory basis financial statements, whereas under GAAP, it is a requirement to present comprehensive income and its components in the financial statements.

REINSURANCE

- **Reinsurance Ceded** — The Company has an insolvency-only reinsurance agreement with UnitedHealthcare Insurance Company ("UHIC"), an affiliate whereby 0.01% of net premium income is ceded to UHIC (see Note 23).
- **Ceded Reinsurance Premiums Payable** — The ceded reinsurance premiums payable balance represents amounts due to the reinsurers for specified coverage which will be paid based on the contract terms.

OTHER

- **Vulnerability Due to Certain Concentrations** — The Company is subject to substantial federal and state government regulation, including licensing and other requirements relating to the offering of the Company's existing products in new markets and offerings of new products, both of which may restrict the Company's ability to expand its business.

The Company has no commercial customers that individually exceed 10% of total direct premiums written and premiums and considerations, including receivables for contracts subject to redetermination, for the years ended December 31, 2020 and 2019.

Direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, from members and CMS related to the Medicare Plans as a

percentage of total direct premiums written and total uncollected premiums, including receivables for contracts subject to redetermination, are less than 1% as of December 31, 2019.

Direct premiums written and uncollected premiums, including receivables for contracts subject to redetermination, from the State of Louisiana, LDH as a percentage of total direct premiums written and total uncollected premiums, including receivables for contracts subject to redetermination, are approximately 100% as of December 31, 2020 and approximately 100% as of December 31, 2019, respectively.

Recently Issued Accounting Standards — The Company reviewed all recently issued guidance in 2020 and 2019 that has been adopted for 2020 or subsequent years' implementation and has determined that none of the items would have a significant impact to the statutory basis financial statements.

D. Going Concern

The Company has the ability and will continue to operate for a period of time sufficient to carry out its commitments, obligations and business objectives.

2. ACCOUNTING CHANGES AND CORRECTIONS OF ERRORS

No changes in accounting principles or corrections of errors have been recorded during the years ended December 31, 2020 and 2019.

3. BUSINESS COMBINATIONS AND GOODWILL

A–D. The Company was not party to a business combination during the years ended December 31, 2020 and 2019, and does not carry goodwill in its statutory basis statements of admitted assets, liabilities, and capital and surplus.

4. DISCONTINUED OPERATIONS

A. Discontinued Operation Disposed of or Classified as Held for Sale

(1–4) The Company did not have any discontinued operations disposed of or classified as held for sale during 2020 and 2019.

B. Change in Plan of Sale of Discontinued Operation — Not applicable.

C. Nature of any Significant Continuing Involvement with Discontinued Operations after Disposal — Not applicable.

D. Equity Interest Retained in the Discontinued Operation after Disposal — Not applicable.

5. INVESTMENTS

For purposes of calculating gross realized gains and losses on sales of investments, the amortized cost of each investment sold is used. The gross realized gains and losses on sales of long-term investments were \$326,203 and \$60,448, respectively, for 2020 and \$163,114 and \$278,601, respectively, for 2019. There were no gross realized gains and losses on sales of short-term investments for 2020 and 2019. The net realized loss is included in net realized capital gains (losses) less taxes in the statutory basis statements of operations. Total proceeds on the sale of long-term investments were \$7,150,976 and \$63,974,963. There were no proceeds on the sales of short-term investments in 2020 and 2019.

As of December 31, 2020 and 2019, the book/adjusted carrying value, fair value, and gross unrecognized unrealized gains and losses of the Company's investments, excluding cash and cash equivalents of \$262,749,920 and \$177,638,046 respectively, are disclosed in the table below.

2020					
	Book/Adjusted Carrying Value	Gross Unrecognized Unrealized Gains	Gross Unrecognized Unrealized Losses < 1 Year	Gross Unrecognized Unrealized Losses > 1 Year	Fair Value
U.S. government and agency securities	\$ 41,733,929	\$ 2,848,156	\$ 53,613	\$ -	\$ 44,528,472
State and agency municipal securities	26,300,405	1,848,179	-	-	28,148,584
City and county municipal securities	50,631,241	3,317,107	-	-	53,948,348
Corporate debt securities	122,760,456	8,431,641	9,365	-	131,182,732
Other invested assets	<u>2,434,863</u>	<u>0</u>	<u>-</u>	<u>-</u>	<u>2,434,863</u>
Total bonds and other invested assets	<u>\$ 243,860,894</u>	<u>\$ 16,445,083</u>	<u>\$ 62,978</u>	<u>\$ -</u>	<u>\$ 260,242,999</u>

2020					
	Book/Adjusted Carrying Value	Gross Unrecognized Unrealized Gains	Gross Unrecognized Unrealized Losses < 1 Year	Gross Unrecognized Unrealized Losses > 1 Year	Fair Value
Less than one year	\$ 9,309,278	\$ 56,799	\$ -	\$ -	\$ 9,366,077
One to five years	107,810,371	5,388,925	882	-	113,198,414
Five to ten years	80,809,110	8,283,812	53,613	-	89,039,309
Over ten years	<u>45,932,135</u>	<u>2,715,547</u>	<u>8,483</u>	<u>-</u>	<u>48,639,199</u>
Total bonds and other invested assets	<u>\$ 243,860,894</u>	<u>\$ 16,445,083</u>	<u>\$ 62,978</u>	<u>\$ -</u>	<u>\$ 260,242,999</u>

2019					
	Book/Adjusted Carrying Value	Gross Unrecognized Unrealized Gains	Gross Unrecognized Unrealized Losses < 1 Year	Gross Unrecognized Unrealized Losses > 1 Year	Fair Value
U.S. government and agency securities	\$ 42,228,395	\$ 1,362,226	\$ 4,666	\$ 50,190	\$ 43,535,765
State and agency municipal securities	24,580,972	1,018,193	833	-	25,598,332
City and county municipal securities	49,751,344	1,818,467	-	-	51,569,811
Corporate debt securities	<u>118,253,362</u>	<u>3,287,318</u>	<u>62,379</u>	<u>6,740</u>	<u>121,471,561</u>
Total bonds	<u>\$ 234,814,073</u>	<u>\$ 7,486,204</u>	<u>\$ 67,878</u>	<u>\$ 56,930</u>	<u>\$ 242,175,469</u>

Included in U.S. government and agency securities and corporate debt securities in the tables above are mortgage-related loan-backed securities, which do not have a single maturity date. For the years to maturity table above, these securities have been presented in the maturity group based on the securities' final maturity date and at a book/adjusted carrying value of \$29,205,446 and fair value of \$30,633,918.

The following table illustrates the fair value and gross unrecognized unrealized losses, aggregated by investment category and length of time that the individual securities have been in a continuous unrecognized unrealized loss position as of December 31, 2020 and 2019:

	2020					
	< 1 Year		> 1 Year		Total	
	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses
U.S. government and agency securities	\$ 3,787,389	\$ 53,613	\$ -	\$ -	\$ 3,787,389	\$ 53,613
Corporate debt securities	<u>2,711,820</u>	<u>9,365</u>	<u>-</u>	<u>-</u>	<u>2,711,820</u>	<u>9,365</u>
Total bonds	<u>\$ 6,499,209</u>	<u>\$ 62,978</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 6,499,209</u>	<u>\$ 62,978</u>

	2019					
	< 1 Year		> 1 Year		Total	
	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses
U.S. government and agency securities	\$ 1,471,061	\$ 4,666	\$ 6,224,024	\$ 50,190	\$ 7,695,085	\$ 54,856
State and agency municipal securities	829,844	833	-	-	829,844	833
Corporate debt securities	<u>10,002,349</u>	<u>62,379</u>	<u>1,121,687</u>	<u>6,740</u>	<u>11,124,036</u>	<u>69,119</u>
Total bonds	<u>\$ 12,303,254</u>	<u>\$ 67,878</u>	<u>\$ 7,345,711</u>	<u>\$ 56,930</u>	<u>\$ 19,648,965</u>	<u>\$ 124,808</u>

The unrecognized unrealized losses on investments in U.S. government and agency securities, state and agency municipal securities, and corporate debt securities at December 31, 2020 and 2019, were mainly caused by interest rate fluctuations and not by unfavorable changes in the credit ratings associated with these securities. The Company evaluates impairment at each reporting period for each of the securities whereby the fair value of the investment is less than its book/adjusted carrying value. The contractual cash flows of the U.S. government and agency securities are guaranteed either by the U.S. government or an agency of the U.S. government. It is expected that the securities would not be settled at a price less than the cost of the investment, and the Company does not intend to sell the investment until the unrealized loss is fully recovered. The Company assessed the credit quality of the state and agency municipal securities, city and county municipal securities and corporate debt securities, noting whether a significant deterioration since purchase or other factors that may indicate an OTTI, such as the length of time and extent to which fair value has been less than cost, the financial condition, and near-term prospects of the issuer as well as specific events or circumstances that may influence the operations of the issuer and the Company's intent to sell the investment. Additionally, the Company evaluated its intent and ability to retain loan-backed securities for a period of time sufficient to recover the amortized cost. As a result of these reviews, the Company recorded an OTTI of \$555,076 and \$0 as of December 31, 2020 and 2019, respectively, which are included in net realized capital gains (losses) less taxes in the statutory basis statements of operations.

A–C. The Company has no mortgage loans, real estate loans, restructured debt, or reverse mortgages. The Company also has no real estate property occupied by the Company, real estate property held for the production of income, or real estate property held for sale.

D. Loan-Backed Securities

- (1) U.S. government and agency securities and corporate debt securities include loan-backed securities (mortgage-backed securities and asset-backed securities), which are valued using the retrospective adjustment methodology. Prepayment assumptions for the determination of the book/adjusted carrying value, commonly referred to as amortized cost, of loan-backed securities are based on a three-month constant prepayment rate history obtained from external data source vendors.

- (2) As of December 31, 2020, the Company has classified loan-backed securities that have OTTI as intent to sell. For the remaining loan-backed securities, the Company has the intent and ability to retain the investment in the security for a period of time sufficient to recover the amortized cost basis and determined that the present value of cash flows to be collected is equal to or exceeds the amortized cost basis of the security, as of December 31, 2020. The table below illustrates the aggregate OTTI recognized on loan-backed securities classified on the basis for the OTTI during 2020:

	1 Amortized Cost Basis Before Other-than- Temporary Impairment	2 Other-than- Temporary Impairment Recognized in Loss	3 Fair Value 1 - 2
OTTI Recognized 1st Quarter			
a. Intent to sell	\$ -	\$ -	\$ -
b. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	-	-	-
c. Total 1st Quarter	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>
OTTI Recognized 2nd Quarter			
d. Intent to sell	\$ 2,117,239	\$ 69,680	\$ 2,047,559
e. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	-	-	-
f. Total 2nd Quarter	<u>\$ 2,117,239</u>	<u>\$ 69,680</u>	<u>\$ 2,047,559</u>
OTTI Recognized 3rd Quarter			
g. Intent to sell	\$ -	\$ -	\$ -
h. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	-	-	-
i. Total 3rd Quarter	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>
OTTI Recognized 4th Quarter			
j. Intent to sell	\$ -	\$ -	\$ -
k. Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	-	-	-
l. Total 4th Quarter	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>
m. Annual aggregate total		<u>\$ 69,680</u>	

The Company did not recognize any OTTI on loan-backed securities due to an inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis, or where the present value of cash flows expected to be collected is less than the amortized cost basis of the security, as of December 31, 2020.

- (3) The table below represents the loan-backed securities with an OTTI for the years ended December 31, 2020 and 2019, presented by CUSIP:

2020						
1	2	3	4	5	6	7
CUSIP	Book/Adjusted Carrying Value Amortized Cost before Current Period OTTI	Present Value of Projected Cash Flows	Recognized Other-than-Temporary Impairment	Amortized Cost After Other-than-Temporary Impairment	Fair Value at Time of OTTI	Date of Financial Statement Where Reported
00432CBN0	\$ 232,929	\$ 223,784	\$ 9,145	\$ 223,784	\$ 223,784	6/30/2020
26828WAA2	351,853	340,534	11,319	340,534	340,534	6/30/2020
64032KAA1	1,171,357	1,135,631	35,726	1,135,631	1,135,631	6/30/2020
64033GAA9	68,564	66,196	2,368	66,196	66,196	6/30/2020
69339QAA7	292,536	281,413	11,122	281,413	281,413	6/30/2020
Total	XXX	XXX	\$ 69,680	XXX	XXX	XXX

2019						
1	2	3	4	5	6	7
CUSIP	Book/Adjusted Carrying Value Amortized Cost before Current Period OTTI	Present Value of Projected Cash Flows	Recognized Other-than-Temporary Impairment	Amortized Cost After Other-than-Temporary Impairment	Fair Value at Time of OTTI	Date of Financial Statement Where Reported
	\$ -	\$ -	\$ -	\$ -	\$ -	
Total	XXX	XXX	\$ -	XXX	XXX	XXX

- (4) The following table illustrates the fair value, gross unrecognized unrealized losses, and length of time that the loan-backed securities have been in a continuous unrecognized unrealized loss position as of December 31, 2020 and 2019:

2020

The aggregate amount of unrealized losses:

1. Less than 12 months	\$ -
2. 12 months or longer	-

The aggregate related fair value of securities with unrealized losses:

1. Less than 12 months	-
2. 12 months or longer	-

2019

The aggregate amount of unrealized losses:

1. Less than 12 months	\$ 43,019
2. 12 months or longer	54,990

The aggregate related fair value of securities with unrealized losses:

1. Less than 12 months	5,382,753
2. 12 months or longer	6,547,982

- (5) The Company believes that it will continue to collect timely the principal and interest due on its loan-backed securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate changes and not by unfavorable

changes in the credit quality associated with these securities that impacted the assessment on collectability of principle and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, and the potential economic impacts of COVID-19 on the issuers, noting no significant credit deterioration since purchase. As of December 31, 2020, the unrealized loss on any security that the Company classified as intent to sell was not material to the Company's investment portfolio. Any other securities in an unrealized loss position as of December 31, 2020, the Company considers to be temporary.

- E. Dollar Repurchase Agreements and/or Securities Lending Transactions** — Not applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing** — Not applicable.
- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing** — Not applicable.
- H. Repurchase Agreements Transactions Accounted for as a Sale** — Not applicable.
- I. Reverse Repurchase Agreements Transactions Accounted for as a Sale** — Not applicable.
- J. Real Estate** — Not applicable.
- K. Low-Income Housing Tax Credits**

(1–7) LIHTC investments of \$2,434,863 and \$0 as of December 31, 2020 and 2019, respectively, are included in other invested assets in the statutory basis statements of admitted assets, liabilities, and capital and surplus. The Company also has a corresponding liability of \$3,983,776 and \$0 as of December 31, 2020 and 2019, respectively, which represents the future capital contributions that will be required as long as the asset is performing based on the agreed upon terms. The number of remaining years of unexpired tax credits is 12 years and the required holding period for the LIHTC investments is 16 years. The LIHTC investments are not currently subject to any regulatory reviews. The Company did not recognize any impairment losses, write-downs, or reclassifications during 2020 or 2019.

L. Restricted Assets

(1) Restricted assets, including pledged securities as of December 31, 2020 and 2019, are presented below:

Restricted Asset Category	1 Total Gross (Admitted & Nonadmitted) Restricted from Current Year	2 Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	3 Increase/ (Decrease) (1 Minus 2)	4 Total Current Year Nonadmitted Restricted	5 Total Current Year Admitted Restricted (1 minus 4)	6 Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	7 Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual obligation for which liability is not shown	\$ -	\$ -	\$ -	\$ -	\$ -	- %	- %
b. Collateral held under security lending agreements	-	-	-	-	-	-	-
c. Subject to repurchase agreements	-	-	-	-	-	-	-
d. Subject to reverse repurchase agreements	-	-	-	-	-	-	-
e. Subject to dollar repurchase agreements	-	-	-	-	-	-	-
f. Subject to dollar reverse repurchase agreements	-	-	-	-	-	-	-
g. Placed under option contracts	-	-	-	-	-	-	-
h. Letter stock or securities restricted as to sale — excluding FHLB capital stock	-	-	-	-	-	-	-
i. FHLB capital stock	-	-	-	-	-	-	-
j. On deposit with states	1,000,000	1,000,000	-	-	1,000,000	-	-
k. On deposit with other regulatory bodies	-	-	-	-	-	-	-
l. Pledged as collateral to FHLB (including assets backing funding agreements)	-	-	-	-	-	-	-
m. Pledged as collateral not captured in other categories	-	-	-	-	-	-	-
n. Other restricted assets	-	-	-	-	-	-	-
o. Total restricted assets	\$ 1,000,000	\$ 1,000,000	\$ -	\$ -	\$ 1,000,000	- %	- %

(a) Column 1 divided by Asset Page, Column 1, Line 28

(b) Column 5 divided by Asset Page, Column 3, Line 28

(2–4) The Company has no assets pledged as collateral not captured in other categories and no other restricted assets as of December 31, 2020 or 2019.

M. **Working Capital Finance Investments** — Not applicable.

N. **Offsetting and Netting of Assets and Liabilities**

The Company does not have any offsetting or netting of assets and liabilities as it relates to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and securities lending activities.

O. **5GI Securities**

The Company does not have any investments with an NAIC designation of 5GI as of December 31, 2020 and 2019.

P. **Short Sales** — Not applicable.

Q. Prepayment Penalty and Acceleration Fees —

The following table illustrates prepayment penalty and acceleration fees as of December 31, 2020:

	General Account
1. Number of CUSIPs	4
2. Aggregate Amount of Investment Income	\$ 88,370

R. Reporting Entity's Share of Cash Pool by Asset Type — Not applicable.

6. JOINT VENTURES, PARTNERSHIPS, AND LIMITED LIABILITY COMPANIES

A–B. The Company has no investments in joint ventures, partnerships, or limited liability companies that exceed 10% of admitted assets and did not recognize any impairment write-down for its investments in joint ventures, partnerships, and limited liability companies during the statement periods.

7. INVESTMENT INCOME

- A.** The Company excludes all investment income due and accrued amounts that are over 90 days past due from the statutory basis statements of admitted assets, liabilities, and capital and surplus.
- B.** There were no investment income amounts excluded from the statutory basis financial statements.

8. DERIVATIVE INSTRUMENTS

A–B. The Company has no derivative instruments.

9. INCOME TAXES

A. Deferred Tax Asset/Liability

- (1)** The components of the net deferred tax asset at December 31, 2020 and 2019 are as follows:

	2020			2019			Change		
	1 Ordinary	2 Capital	3 (Col 1 + 2) Total	4 Ordinary	5 Capital	6 (Col 4 + 5) Total	7 (Col 1 - 4) Ordinary	8 (Col 2 - 5) Capital	9 (Col 7 + 8) Total
(a) Gross deferred tax assets	\$ 14,081,007	\$ -	\$ 14,081,007	\$ 13,585,830	\$ 13	\$ 13,585,843	\$ 495,177	\$ (13)	\$ 495,164
(b) Statutory valuation allowance adjustments	-	-	-	-	-	-	-	-	-
(c) Adjusted gross deferred tax assets (1a - 1b)	14,081,007	-	14,081,007	13,585,830	13	13,585,843	495,177	(13)	495,164
(d) Deferred tax assets nonadmitted	-	-	-	-	-	-	-	-	-
(e) Subtotal net admitted deferred tax asset (1c - 1d)	14,081,007	-	14,081,007	13,585,830	13	13,585,843	495,177	(13)	495,164
(f) Deferred tax liabilities	220,662	-	220,662	288,750	3,283	292,033	(68,088)	(3,283)	(71,371)
(g) Net admitted deferred tax asset/(net deferred tax liability) (1e - 1f)	<u>\$ 13,860,345</u>	<u>\$ -</u>	<u>\$ 13,860,345</u>	<u>\$ 13,297,080</u>	<u>\$ (3,270)</u>	<u>\$ 13,293,810</u>	<u>\$ 563,265</u>	<u>\$ 3,270</u>	<u>\$ 566,535</u>

- (2) The components of the adjusted gross deferred tax assets admissibility calculation under Statement of Statutory Accounting Principles ("SSAP") No. 101, *Income Taxes*, are as follows:

Admission Calculation Components SSAP No. 101	2020			2019			Change		
	1 Ordinary	2 Capital	3 (Col 1 + 2) Total	4 Ordinary	5 Capital	6 (Col 4 + 5) Total	7 (Col 1 - 4) Ordinary	8 (Col 2 - 5) Capital	9 (Col 7 + 8) Total
(a) Federal income taxes paid in prior years recoverable through loss carrybacks	\$ 14,081,007	\$ -	\$ 14,081,007	\$ 13,585,830	\$ -	\$ 13,585,830	\$ 495,177	\$ -	\$ 495,177
(b) Adjusted gross deferred tax assets expected to be realized (excluding the amount of deferred tax assets from 2(a) above) after application of the threshold limitation. (The lesser of 2(b)1 and 2(b)2 below)	-	-	-	-	-	-	-	-	-
1. Adjusted gross deferred tax assets expected to be realized following the balance sheet date	-	-	-	-	-	-	-	-	-
2. Adjusted gross deferred tax assets allowed per limitation threshold	XXX	XXX	37,717,818	XXX	XXX	17,172,010	XXX	XXX	20,545,808
(c) Adjusted gross deferred tax assets (excluding the amount of deferred tax assets from 2(a) and 2(b) above) offset by gross deferred tax liabilities	-	-	-	-	13	13	-	(13)	(13)
(d) Deferred tax assets admitted as the result of application of SSAP No. 101 Total (2(a) + 2(b) + 2(c))	<u>\$ 14,081,007</u>	<u>\$ -</u>	<u>\$ 14,081,007</u>	<u>\$ 13,585,830</u>	<u>\$ 13</u>	<u>\$ 13,585,843</u>	<u>\$ 495,177</u>	<u>\$ (13)</u>	<u>\$ 495,164</u>

- (3) The ratio percentage and adjusted capital and surplus used to determine the recovery period and threshold limitations for the admissibility calculation are presented below:

	2020	2019
(a) Ratio percentage used to determine recovery period and threshold limitation amount	379 %	249 %
(b) Amount of adjusted capital and surplus used to determine recovery period and threshold limitation in 2(b)(2) above	\$ 251,452,119	\$ 171,720,100

- (4) The impact to the gross deferred tax assets balances as a result of tax-planning strategies as of December 31, 2020 and 2019 is presented below:

Impact of Tax-Planning Strategies	2020		2019		Change	
	1	2	3	4	5	6
	Ordinary	Capital	Ordinary	Capital	(Col 1 - 3) Ordinary	(Col 2 - 4) Capital
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets by tax character as a percentage.						
1. Adjusted gross DTAs amount from Note 9A1(c)	\$ 14,081,007	\$ -	\$ 13,585,830	\$ 13	\$ 495,177	\$ (13)
2. Percentage of adjusted gross DTAs by tax character attributable to the impact of tax-planning strategies	- %	- %	- %	- %	- %	- %
3. Net admitted adjusted gross DTAs amount from Note 9A1(e)	\$ 14,081,007	\$ -	\$ 13,585,830	\$ 13	\$ 495,177	\$ (13)
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax-planning strategies	- %	- %	- %	- %	- %	- %
(b) Does the Company's tax-planning strategies include the use of reinsurance?			Yes		No	X

B. Unrecognized Deferred Tax Liabilities

- (1-4) There are no unrecognized deferred tax liabilities for the years ended December 31, 2020 and 2019.

C. Significant Components of Income Taxes

- (1) The current federal income taxes incurred for the years ended December 31, 2020 and 2019 are as follows:

	1	2	3
	2020	2019	(Col 1 - 2) Change
1. Current income tax			
(a) Federal	\$ 33,166,495	\$ 7,633,194	\$ 25,533,301
(b) Foreign	-	-	-
(c) Subtotal	33,166,495	7,633,194	25,533,301
(d) Federal income tax on net capital gains (losses)	(61,394)	(15,440)	(45,954)
(e) Utilization of capital loss carryforwards	-	-	-
(f) Other	-	-	-
(g) Total federal and foreign income taxes incurred (benefit)	<u>\$ 33,105,101</u>	<u>\$ 7,617,754</u>	<u>\$ 25,487,347</u>

(2-4) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and liabilities as of December 31, 2020 and 2019, are as follows:

	1	2	3
	2020	2019	(Col 1 - 2) Change
2 Deferred tax assets:			
(a) Ordinary:			
(1) Discounting of unpaid losses	\$ 1,071,861	\$ 1,022,393	\$ 49,468
(2) Unearned premium reserve	13,448	5,956	7,492
(3) Policyholder reserves	-	4,878,930	(4,878,930)
(4) Investments	-	-	-
(5) Deferred acquisition costs	-	-	-
(6) Policyholder dividends accrual	-	-	-
(7) Fixed assets	-	-	-
(8) Compensation and benefits accrual	-	-	-
(9) Pension accrual	-	-	-
(10) Receivables — nonadmitted	12,995,667	7,678,158	5,317,509
(11) Net operating loss carryforward	-	-	-
(12) Tax credit carryforward	-	-	-
(13) Other (including items <5% of total ordinary tax assets)	31	393	(362)
(99) Subtotal	14,081,007	13,585,830	495,177
(b) Statutory valuation allowance adjustment	-	-	-
(c) Nonadmitted	-	-	-
(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	14,081,007	13,585,830	495,177
(e) Capital:			
(1) Investments	-	-	-
(2) Net capital loss carryforward	-	-	-
(3) Real estate	-	-	-
(4) Other (including items <5% of total capital tax assets)	-	13	(13)
(99) Subtotal	-	13	(13)
(f) Statutory valuation allowance adjustment	-	-	-
(g) Nonadmitted	-	-	-
(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	-	13	(13)
(i) Admitted deferred tax assets (2d + 2h)	14,081,007	13,585,843	495,164
3 Deferred tax liabilities:			
(a) Ordinary:			
(1) Investments	-	23,956	(23,956)
(2) Fixed assets	-	-	-
(3) Deferred and uncollected premium	-	-	-
(4) Policyholder reserves	-	-	-
(5) Other (including items <5% of total ordinary tax liabilities)	220,662	264,794	(44,132)
(99) Subtotal	220,662	288,750	(68,088)
(b) Capital:			
(1) Investments	-	3,212	(3,212)
(2) Real estate	-	-	-
(3) Other (including items <5% of total capital tax liabilities)	-	71	(71)
(99) Subtotal	-	3,283	(3,283)
(c) Deferred tax liabilities (3a99 + 3b99)	220,662	292,033	(71,371)
4 Net deferred tax assets/liabilities (2i - 3c)	\$ 13,860,345	\$ 13,293,810	\$ 566,535

The other ordinary deferred tax liability of \$220,662 for 2020 and \$264,794 for 2019 consists of discounting of unpaid losses. The other capital deferred tax asset of \$13 for 2019 consists of unrealized losses.

The Company assessed the potential realization of the gross deferred tax asset and as a result no statutory valuation allowance was required and no allowance was established as of December 31, 2020 and 2019.

- D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory federal income tax rate of 21% to net income before federal income taxes incurred, less capital gains (benefit). A summarization of the significant items causing this difference as of December 31, 2020 and 2019 is as follows:

	2020		2019	
	Amount	Effective Tax Rate	Amount	Effective Tax Rate
Tax provision at the federal statutory rate	\$ 29,013,362	21 %	\$ 11,872,127	21 %
Tax-exempt interest	(241,672)	-	(257,722)	(1)
Health insurer fee	9,084,443	6	-	-
Tax effect of nonadmitted assets	(5,317,509)	(4)	(2,699,082)	(5)
Prior year true-up	(1,183,980)	(1)	6,716,220	12
Prior year audited financial statement adjustment, net with true-up above	1,183,980	1	(4,789,890)	(8)
Deferred corrections	-	-	(1,926,330)	(3)
Total statutory income taxes	<u>\$ 32,538,624</u>	<u>23 %</u>	<u>\$ 8,915,323</u>	<u>16 %</u>
Federal income taxes incurred	\$ 33,166,495	23 %	\$ 7,633,194	14 %
Capital gains tax	(61,394)	-	(15,440)	-
Change in net deferred income tax	<u>(566,477)</u>	<u>-</u>	<u>1,297,569</u>	<u>2</u>
Total statutory income taxes	<u>\$ 32,538,624</u>	<u>23 %</u>	<u>\$ 8,915,323</u>	<u>16 %</u>

- E. At December 31, 2020, the Company had no net operating loss carryforwards.

Current federal income tax payable of \$751,100 and \$4,258,754 as of December 31, 2020 and 2019, respectively, are included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Federal income taxes paid, net of refunds were \$36,612,755 and \$22,083,065 in 2020 and 2019, respectively.

Federal income taxes incurred of \$33,105,101 and \$7,617,755 for 2020 and 2019, respectively, are available for recoupment in the event of future net losses.

The Company has not admitted any aggregate amounts of deposits that are included within Section 6603 ("Deposits made to suspend running of interest on potential underpayments, etc.") of the Internal Revenue Service ("IRS") Code.

- F. The Company is included in the consolidated federal income tax return with its ultimate parent, UnitedHealth Group. The entities included within the consolidated return are included in NAIC Statutory Statement Schedule Y — Information Concerning Activities of Insurer Members Of A Holding Company Group. Federal income taxes are paid to or refunded by UnitedHealth Group pursuant to the terms of a tax-sharing agreement, approved by the Board of Directors, under which taxes approximate the amount that would have been computed on a separate company basis, with the exception of net operating losses and capital losses. For these losses, the Company receives a benefit at the federal rate in the current year for current taxable losses incurred in that year to the extent losses can be utilized in the consolidated federal income tax return of UnitedHealth Group. UnitedHealth Group currently files income tax returns in the U.S. federal jurisdiction, various states, and foreign jurisdictions. The IRS has completed exams on UnitedHealth Group's consolidated income tax returns for fiscal years 2016 and prior.

UnitedHealth Group's 2017 through 2020 tax returns are under review by the IRS under its Compliance Assurance Program. With the exception of a few states, UnitedHealth Group is no longer subject to income tax examinations prior to the 2013 tax year. In general, the Company is subject to examination in non-U.S. jurisdictions for years 2015 and forward. The Company does not believe any adjustments that may result from these examinations will be material to the Company.

- G. Tax Contingencies** — Not applicable.
- H. Repatriation Transition Tax** — Not applicable.
- I. Alternative Minimum Tax Credit** — Not applicable.

10. INFORMATION CONCERNING PARENT, SUBSIDIARIES, AND AFFILIATES

- A–B.** In the ordinary course of business, the Company contracts with several affiliates to provide a wide variety of services to the Company's members. These agreements are filed with and approved by the LADOI according to Management's understanding of the current requirements and standards. Within the confines of the applicable filed and approved agreements (including subsequent amendments thereto), the amount and types of services provided by these affiliated entities can change year over year.

The Company has a tax-sharing agreement with UnitedHealth Group (see Note 9).

The Company holds a \$100,000,000 subordinated revolving credit agreement with UnitedHealth Group at an interest rate of London InterBank Offered Rate plus a margin of 0.50%. This credit agreement is subordinate to the extent it does not conflict with any credit facility held by either party. The credit agreement is enforced unless terminated by either party. No amounts were outstanding under the line of credit as of December 31, 2020 and 2019.

The Company has entered into a reinsurance agreement with an affiliated entity (see Note 23).

C. Transactions With Related Parties Who Are Not Reported On Schedule Y

The Company has no material related party transactions that meet the disclosure requirements pursuant to SSAP No. 25, *Affiliates and Other Related Parties* ("SSAP No. 25") that are not included in NAIC Statutory Statement Schedule Y — Part 2 Summary Of Insurer's Transactions With Any Affiliates.

- D.** At December 31, 2020 and 2019, the Company reported \$5,032,641 and \$11,436,936, respectively, as amounts due to parent, subsidiaries and affiliates, which are included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. These balances are generally settled within 90 days from the incurred date. Any balances due to the Company that are not settled within 90 days are considered nonadmitted assets.
- E.** The administrative services, access fees, and cost of care services provided by affiliates are calculated using one or more of the following methods: (1) a percentage of premiums; (2) use of assets; (3) direct pass-through of charges; (4) per member per month; (5) per employee per month; (6) per claim; or (7) a combination thereof consistent with the provisions contained in each contract. These amounts are included in GAE, CAE, and total hospital and medical expense in the statutory basis statements of operations. The following table identifies the amounts reported for the administrative services, access fees, and cost of care services provided by related parties

for the years ended December 31, 2020 and 2019, which meet the disclosure requirements pursuant to SSAP No. 25, regardless of the effective date of the contract:

	2020	2019
OptumRx, Inc.	\$ 555,229,485	\$ 427,129,037
United HealthCare Services, Inc.	112,636,282	127,999,185
United Behavioral Health	27,282,868	26,448,952
OptumInsight, Inc.	3,075,659	3,213,028
AxelaCare Intermediate Holdings, LLC	-	8,787,370

OptumRx provides services that may include, but are not limited to, administrative services related to pharmacy management and pharmacy claims processing for enrollees, manufacturer rebate administration, pharmacy incentive services, specialty drug pharmacy services, durable medical equipment services including orthotics and prosthetics and personal health products catalogues showing the healthcare products and benefit credits enrollees needed to redeem the respective products.

UHS provides, or arranges for the provision of, management, administrative, and other services deemed necessary or appropriate for UHS to provide management and operational support to the Company. The services can include, but are not limited to, the categories of management and operational services outlined in the Agreement, such as human resources, legal, facilities, general administration, treasury and investment functions, claims adjudication and payment, benefit administration, disease management, health care decision support, medical management, credentialing, preventative health services, and utilization management reporting.

United Behavioral Health provides services related to mental health and substance abuse treatment.

OptumInsight, Inc. provides services that may include, but are not limited to, claim analytics and recovery of medical expense overpayments, retroactive fraud, waste and abuse, subrogation and premium audit services. All recoveries are returned to the Company by OptumInsight, Inc. on a monthly basis.

AxelaCare Intermediate Holdings, LLC provides home infusion therapy services.

The Company has premium payments that are received and claim payments and direct expenses such as broker commissions, LADOI exam fees, ACA assessments and premium taxes that are processed and paid by an affiliated UnitedHealth Group entity. Premiums, claims, and direct expenses applicable to the Company are settled at regular intervals throughout the month via the intercompany settlement process and any amounts outstanding are reflected in amounts due to parent, subsidiaries, and affiliates, net in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

- F. The Company has not extended any guarantees or undertakings for the benefit of an affiliate or related party.
- G. The Company is part of an insurance holding company system with UnitedHealth Group as the ultimate parent. Management believes that the Company's transactions with affiliates are fair and reasonable; however, operations of the Company may not be indicative of those that would have occurred if it had operated as an independent company.
- H. The Company does not have any amount deducted from the value of an upstream intermediate entity or ultimate parent owned, either directly or indirectly, via a downstream subsidiary, controlled, or affiliated entity.

- I.** The Company does not have any investments in a subsidiary, controlled, or affiliated entity that exceeds 10% of admitted assets.
- J.** The Company does not have any investments in impaired subsidiaries, controlled, or affiliated entities.
- K.** The Company does not have any investments in foreign insurance subsidiaries.
- L.** The Company does not hold any investments in a downstream noninsurance holding company.
- M.** The Company does not have any investments in noninsurance subsidiaries, controlled, or affiliated entities.
- N.** The Company does not have any investments in insurance subsidiaries, controlled, or affiliated entities.
- O.** The Company does not have any investments in subsidiary, controlled, or affiliated entities or joint ventures, partnerships and limited liability companies in which the Company's share of losses exceeds the investment.

11. DEBT

- A–B.** The Company had no outstanding debt with third-parties or outstanding Federal Home Loan Bank agreements during 2020 and 2019.

12. RETIREMENT PLANS, DEFERRED COMPENSATION, POSTEMPLOYMENT BENEFITS AND COMPENSATED ABSENCES AND OTHER POSTRETIREMENT BENEFIT PLANS

- A–I.** The Company has no defined benefit plans, defined contribution plans, multiemployer plans, consolidated/holding company plans, postemployment benefits, or compensated absences plans and is not impacted by the Medicare Modernization Act on postretirement benefits, since all personnel are employees of UHS, which provides services to the Company under the terms of the Agreement (see Note 10).

13. CAPITAL AND SURPLUS, DIVIDEND RESTRICTIONS, AND QUASI-REORGANIZATIONS

- A–B.** The Company has 1,000,000 shares authorized and 900,000 shares issued and outstanding of \$2 par value common stock. The Company has no preferred stock outstanding. All issued and outstanding shares of common stock are held by the Company's parent, UHC.
- C.** Dividend payment requirements are outlined in the domiciliary state statutes and may be further restricted by the LADOI.
- D.** The Company paid no dividends and no infusions were received during 2020 or 2019.
- E.** The amount of ordinary dividends that may be paid out during any given period is subject to certain restrictions as specified by state statute.
- F.** There are no restrictions placed on the Company's unassigned surplus.
- G.** The Company is not a mutual reciprocal or a similarly organized entity and does not have advances to surplus not repaid.

- H. The Company does not hold any stock, including stock of affiliated companies for special purposes, such as conversion of preferred stock, employee stock options, or stock purchase warrants.
- I. As discussed in Note 1, in 2020 no amount was required to be apportioned out of unassigned surplus as the HIF was repealed by Congress, effective January 1, 2021. For the year ended December 31, 2019, the amount of the estimated Section 9010 ACA subsequent fee year assessment apportioned out of unassigned surplus was \$43,016,618.
- J. The portion of unassigned surplus, excluding the apportionment of estimated Section 9010 ACA subsequent fee year assessment, and net income, represented (or reduced) by each item below is as follows:

	2020	2019
Unrealized capital (losses) gains on investments	\$ -	\$ 276
Net deferred income taxes	13,860,345	13,293,810
Nonadmitted assets	<u>(61,884,129)</u>	<u>(36,562,656)</u>
Total	<u>\$ (48,023,784)</u>	<u>\$ (23,268,570)</u>

- K–M. The Company does not have any outstanding surplus notes and has never been a party to a quasi-reorganization.

14. LIABILITIES, CONTINGENCIES AND ASSESSMENTS

A. Contingent Commitments

The Company has given LIHTC a commitment for additional investment in the form of an equity contribution that will be required as long as the assets are performing based on the agreed upon contractual terms. The Company has the ability to sell its interest in the LIHTC investment prior to the additional contribution being required. The current amount of the commitment for additional investment is not to exceed the aggregate \$3,983,776 as of December 31, 2020.

B. Assessments

The Company is not aware of any guaranty fund assessments or premium tax offsets, potential or accrued, that could have a material financial effect on the operations of the entity.

C. Gain Contingencies

The Company is not aware of any gain contingencies that should be disclosed in the statutory basis financial statements.

D. Claims Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits — Not applicable.

E. Joint and Several Liabilities — Not applicable.

F. All Other Contingencies

The Company's business is regulated at the federal, state, and local levels. The laws and rules governing the Company's business and interpretations of those laws and rules are subject to frequent change. Broad latitude is given to the agencies administering those regulations. Further, the Company must obtain and maintain regulatory approvals to market and sell many of its products.

The Company has been, or is currently involved, in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments and other governmental authorities. The Company cannot reasonably estimate the range of loss, if any, that may result from any material government investigations, audits and reviews in which it is currently involved given the inherent difficulty in predicting regulatory action, fines and penalties, if any, and the various remedies and levels of judicial review available to the Company in the event of an adverse finding.

On February 14, 2017, the Department of Justice ("DOJ") announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower's complaint, which was unsealed on February 15, 2017, alleges that the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company's motion to dismiss. In May 2018, the DOJ moved to dismiss the Company's counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government's motion for partial summary judgment and dismissed the Company's counterclaims without prejudice. The Company cannot reasonably estimate the outcome that may result from this matter given its procedural status.

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company's businesses, including management and administration of health benefit plans and other services.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters involve: indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility, or it is probable that a loss may be incurred. Although the outcomes of any such legal actions cannot be predicted, in the opinion of management, the resolution of any currently pending or threatened actions will not have a material adverse effect on the statutory basis statements of admitted assets, liabilities, and capital and surplus or statutory basis statements of operations of the Company.

The Company routinely evaluates the collectability of all receivable amounts included in the statutory basis statements of admitted assets, liabilities, and capital and surplus. Impairment reserves are established for those amounts where collectability is uncertain. Based on the Company's past experience, exposure related to uncollectible balances and the potential of loss for those balances not currently reserved for is not material to the Company's statutory basis financial condition.

There are no assets that the Company considers to be impaired at December 31, 2020 and 2019, except as disclosed in Note 5.

15. LEASES

A–B. According to the Agreement between the Company and UHS (see Note 10), operating leases for the rental of office facilities and equipment are the responsibility of UHS. Fees associated with the lease agreements are included as a component of the Company's management fee.

16. INFORMATION ABOUT FINANCIAL INSTRUMENTS WITH OFF-BALANCE-SHEET RISK AND FINANCIAL INSTRUMENTS WITH CONCENTRATIONS OF CREDIT RISK

(1–4) The Company does not hold any financial instruments with off-balance-sheet risk or have any concentrations of credit risk.

17. SALE, TRANSFER, AND SERVICING OF FINANCIAL ASSETS AND EXTINGUISHMENTS OF LIABILITIES

A–C. The Company did not participate in any transfer of receivables, financial assets or wash sales.

18. GAIN OR LOSS TO THE REPORTING ENTITY FROM UNINSURED PLANS AND THE UNINSURED PORTION OF PARTIALLY INSURED PLANS

A–B. The Company has no operations from Administrative Services Only Contracts or Administrative Services Contracts in 2020 and 2019.

C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract

The Medicare Part D program is a partially insured plan. The Company recorded a receivable of \$175,058 and \$185,911 at December 31, 2020 and 2019, respectively, for cost reimbursement under the Medicare Part D program for the catastrophic reinsurance and low-income member cost-sharing subsidies. The Company also recorded a receivable of \$0 and \$31,823 and also a payable of \$58,572 and \$52,913 at December 31, 2020 and 2019, respectively, for the Medicare Part D CGDP. The receivables and payables are recorded in amounts receivable relating to uninsured plans and liability for amounts held under uninsured plans, respectively, in the statutory basis statements of admitted assets, liabilities and capital and surplus. These Medicare subsidies are described in Note 1, *Amounts Receivable Relating to Uninsured Plans and Liability for Amounts Held Under Uninsured Plans*.

The Company participates in administering payments for the LDH's Managed Care Incentive Program ("MCIP"), which incentivizes hospitals to meet certain individualized metrics. Once a hospital meets these incentives, they are compensated for their efforts in helping the Medicaid populations. There is no risk to the Company as a result of these transactions. The Company has no payables recorded as of December 31, 2020 and 2019, respectively, for the additional pass-through payments to providers. The payments processed for the MCIP were \$112,873,131 and \$34,269,790 as of December 31, 2020 and 2019, respectively.

19. DIRECT PREMIUM WRITTEN/PRODUCED BY MANAGING GENERAL AGENTS/THIRD-PARTY ADMINISTRATORS

The Company did not have any direct premiums written or produced by managing general agents or third-party administrators in 2020 and 2019.

20. FAIR VALUE MEASUREMENTS

The NAIC SAP defines fair value, establishes a framework for measuring fair value, and outlines the disclosure requirements related to fair value measurements. The fair value hierarchy is as follows:

Level 1 — Quoted (unadjusted) prices for identical assets in active markets.

Level 2 — Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets in active markets;
- Quoted prices for identical or similar assets in nonactive markets (few transactions, limited information, noncurrent prices, high variability over time, etc.);
- Inputs other than quoted prices that are observable for the asset (interest rates, yield curves, volatilities, default rates, etc.);
- Inputs that are derived principally from or corroborated by other observable market data.

Level 3 — Unobservable inputs that cannot be corroborated by observable market data.

The estimated fair values of bonds and cash equivalents (collectively “investment holdings”) are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (“pricing service”), which generally uses quoted prices or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, non-binding broker quotes, benchmark yields, credit spreads, default rates, and prepayment speeds. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to a secondary pricing source, prices reported by its custodian, its investment consultant, and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company’s internal price verification procedures and review of fair value methodology documentation provided by independent pricing services have not historically resulted in an adjustment in the prices obtained from the pricing service.

In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

A. Fair Value

(1) Fair Value Measurements at Reporting Date

The following tables present information about the Company’s financial assets that are measured and reported at fair value at December 31, 2020 and 2019, in the statutory basis

statements of admitted assets, liabilities, and capital and surplus according to the valuation techniques the Company used to determine their fair values:

Description for Each Class of Asset or Liability	December 31, 2020				Total
	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	
a. Assets at fair value:					
Perpetual preferred stock:					
Industrial and misc	\$ -	\$ -	\$ -	\$ -	\$ -
Parent, subsidiaries, and affiliates	-	-	-	-	-
Total perpetual preferred stocks	-	-	-	-	-
Bonds:					
U.S. governments	-	-	-	-	-
Industrial and misc	-	-	-	-	-
Hybrid securities	-	-	-	-	-
Parent, subsidiaries, and affiliates	-	-	-	-	-
Total bonds	-	-	-	-	-
Common stock:					
Industrial and misc	-	-	-	-	-
Parent, subsidiaries, and affiliates	-	-	-	-	-
Total common stocks	-	-	-	-	-
Derivative assets:					
Interest rate contracts	-	-	-	-	-
Foreign exchange contracts	-	-	-	-	-
Credit contracts	-	-	-	-	-
Commodity futures contracts	-	-	-	-	-
Commodity forward contracts	-	-	-	-	-
Total derivatives	-	-	-	-	-
Money-market funds	262,697,267	-	-	-	262,697,267
Separate account assets	-	-	-	-	-
Total assets at fair value/NAV	<u>\$ 262,697,267</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 262,697,267</u>
b. Liabilities at fair value:					
Derivative liabilities	\$ -	\$ -	\$ -	\$ -	\$ -
Total liabilities at fair value	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

Description for Each Class of Asset or Liability	December 31, 2019				Total
	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	
a. Assets at fair value:					
Perpetual preferred stock:					
Industrial and misc	\$ -	\$ -	\$ -	\$ -	\$ -
Parent, subsidiaries, and affiliates	-	-	-	-	-
Total perpetual preferred stocks	-	-	-	-	-
Bonds:					
U.S. governments	-	-	-	-	-
Industrial and misc	-	-	-	-	-
Hybrid securities	-	-	-	-	-
Parent, subsidiaries, and affiliates	-	-	-	-	-
Total bonds	-	-	-	-	-
Common stock:					
Industrial and misc	-	-	-	-	-
Parent, subsidiaries, and affiliates	-	-	-	-	-
Total common stocks	-	-	-	-	-
Derivative assets:					
Interest rate contracts	-	-	-	-	-
Foreign exchange contracts	-	-	-	-	-
Credit contracts	-	-	-	-	-
Commodity futures contracts	-	-	-	-	-
Commodity forward contracts	-	-	-	-	-
Total derivatives	-	-	-	-	-
Money-market funds	177,592,989	-	-	-	177,592,989
Separate account assets	-	-	-	-	-
Total assets at fair value/NAV	<u>\$ 177,592,989</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 177,592,989</u>
b. Liabilities at fair value:					
Derivative liabilities	\$ -	\$ -	\$ -	\$ -	\$ -
Total liabilities at fair value	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

- (2) The Company does not have any financial assets with a fair value hierarchy of Level 3 that were measured and reported at fair value.

The Company considers its investments in LIHTC investments a Level 3 investment even though no market valuation was required as of December 31, 2020 and 2019. As a result, these investments are excluded from being presented as a Level 3 security in the fair value hierarchy tables above. As there is no readily available market, these securities are recorded at book/adjusted carrying value and considered held to maturity as they will not be sold. As a result, these investments are recorded and reported at book value of \$2,434,863 and \$0 as of December 31, 2020 and 2019.

- (3) Transfers between fair value hierarchy levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the years ended December 31, 2020 or 2019.
- (4) The framework the Company has established for determining the fair value of the investment holdings is outlined above.

LIHTC Investments — The Company does consider its investments in LIHTC investments as a Level 3 investment even though no market valuation adjustment was required as of December 31, 2020 and 2019, as. As a result these investments are excluded from being presented as a level 3 security in the financial hierarchy tables above. As there is no readily available market, these securities are recorded and reported at book/adjusted carrying value and considered held to maturity as they will not be sold. Should any contractual breakage occur that jeopardizes the ability to receive the tax credits associated with these securities, impairments will be recognized. As of December 31, 2020, all of these investments are performing in accordance with their original contract terms.

(5) The Company has no derivative assets and liabilities to disclose.

B. Fair Value Combination — Not applicable.

C. Aggregate Fair Value Hierarchy

The aggregate fair value by hierarchy of all financial instruments as of December 31, 2020 and 2019 is presented in the table below:

Type of Financial Instrument	December 31, 2020					Net Asset Value (NAV)	Not Practicable (Carrying Value)
	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)		
U.S. government and agency securities	\$ 44,528,472	\$ 41,733,929	\$ 15,651,013	\$ 28,877,459	\$ -	\$ -	\$ -
State and agency municipal securities	28,148,584	26,300,405	-	28,148,584	-	-	-
City and county municipal securities	53,948,348	50,631,241	-	53,948,348	-	-	-
Corporate debt securities	131,182,732	122,760,456	-	131,182,732	-	-	-
Cash equivalents	262,697,267	262,697,267	262,697,267	-	-	-	-
Other invested assets	2,434,863	2,434,863	-	-	2,434,863	-	-
Total bonds, cash equivalents, and other invested assets	<u>\$ 522,940,266</u>	<u>\$ 506,558,161</u>	<u>\$ 278,348,280</u>	<u>\$ 242,157,123</u>	<u>\$ 2,434,863</u>	<u>\$ -</u>	<u>\$ -</u>

Type of Financial Instrument	December 31, 2019					Net Asset Value (NAV)	Not Practicable (Carrying Value)
	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)		
U.S. government and agency securities	\$ 43,535,765	\$ 42,228,395	\$ 10,931,140	\$ 32,604,625	\$ -	\$ -	\$ -
State and agency municipal securities	25,598,332	24,580,972	-	25,598,332	-	-	-
City and county municipal securities	51,569,811	49,751,344	-	51,569,811	-	-	-
Corporate debt securities	121,471,561	118,253,362	-	121,471,561	-	-	-
Cash equivalents	177,592,989	177,592,989	177,592,989	-	-	-	-
Total bonds and cash equivalents	<u>\$ 419,768,458</u>	<u>\$ 412,407,062</u>	<u>\$ 188,524,129</u>	<u>\$ 231,244,329</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

D. Not Practicable to Estimate Fair Value — Not applicable.

E. Investments Measured Using the NAV Practical Expedient — Not applicable.

21. OTHER ITEMS

COVID-19 Trends and Uncertainties

The COVID-19 pandemic continues to evolve and the ultimate impact on the Company and its statutory basis results of operations, financial condition and cash flows remains uncertain. During the second quarter, the global health system experienced unprecedented levels of care deferral. As the pandemic advanced, access to and demand for care was most constrained from mid-March through April, began to recover in May and June and restored to near normal seasonal levels in the third quarter. Care patterns continued to normalize in the fourth quarter, including COVID-19 treatment and testing costs. The temporary deferral of care experienced in 2020 may cause care patterns to moderately exceed normal baselines in future periods as utilization of health system capacity continues to increase. The Company has taken various measures which could include expanded benefit coverage in areas such as

COVID-19 care and testing, telemedicine, and pharmacy benefits; provided customers assistance in the form of co-pay waivers and premium forgiveness; offered additional enrollment opportunities to those who previously declined employer-sponsored offerings; extended certain premium payment terms for customers experiencing financial hardship; simplified administrative practices; and accelerated payments to care providers, all with the aim of assisting customers, care providers, members and communities in addressing the COVID-19 crisis. Temporary care deferrals impacted the Company's results of operations for the year ended December 31, 2020. The impact of temporary care deferrals was partially offset by COVID-19 related care and testing, the financial assistance provided to customers, rebate requirements and broader economic impacts.

Increased consumer demand for care, potentially even higher acuity care, along with continued COVID-19 care and testing costs may result in increased future medical costs. Disrupted care patterns, as a result of the pandemic, may temporarily affect the ability to obtain complete member health status information, impacting future revenue in businesses utilizing risk adjustment methodologies. The ultimate overall impact is uncertain and dependent on the future pacing and intensity of the pandemic, the duration of policies and initiatives to address COVID-19, and general economic uncertainty.

Throughout 2020, the Company's ultimate parent announced a number of programs to directly support people affected by the COVID-19 pandemic, including a plan to grant premium credits to the Company's fully insured commercial customers. The total amount of premium credits granted through December 31, 2020 of \$21,707 has been reflected as a reduction to net premium income in the statutory basis statements of revenue and expenses.

A. Unusual or Infrequent Items

The Company did not encounter any unusual or infrequent items for the years ended December 31, 2020 and 2019.

B. Troubled Debt Restructuring: Debtors

The Company has no troubled debt restructurings as of December 31, 2020 and 2019.

C. Other Disclosures

The Company does not have any amounts not recorded in the statutory basis financial statements that represent segregated funds held for others. The Company also does not have any exposures related to forward commitments that are not derivative instruments.

D. Business Interruption Insurance Recoveries

The Company has not received any business interruption insurance recoveries during 2020 and 2019.

E. State Transferable and Non-transferable Tax Credits

The Company has no transferable or non-transferable state tax credits.

F. Sub-Prime Mortgage-Related Risk Exposure

- (1) The investment policy for the Company limits investments in loan-backed securities, which includes sub-prime issuers. Further, the policy limits investments in private-issuer mortgage securities to 10% of the portfolio, which also includes sub-prime issuers. The exposure to unrealized losses on sub-prime issuers is due to changes in market prices. There are no realized losses due to not receiving anticipated cash flows. The investments covered have an NAIC designation of 1.

- (2) The Company has no direct exposure through investments in sub-prime mortgage loans.
- (3) The Company has no direct exposure through other investments.
- (4) The Company has no underwriting exposure to sub-prime mortgage risk through mortgage guaranty or financial guaranty insurance coverage.

G. Retained Assets

The Company does not have any retained asset accounts for beneficiaries.

H. Insurance-Linked Securities Contracts

As of December 31, 2020, the Company is not aware of any possible proceeds of insurance-linked securities.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy — Not applicable.

22. EVENTS SUBSEQUENT

Subsequent events have been evaluated through April 16, 2021, which is the date these statutory basis financial statements were available for issuance.

TYPE I — Recognized Subsequent Events

Any material Type I events subsequent to December 31, 2020, have been recognized in the statutory basis financial statements and corresponding disclosures.

TYPE II — Non-Recognized Subsequent Events

For the years ended December 31, 2020 and 2019, the Company was subject to the annual fee under Section 9010 of the ACA. The fee is allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of the health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1, of the year the fee is due. The HIF was repealed by Congress, effective January 1, 2021.

The table below presents information regarding the annual fee under Section 9010 of the ACA as of December 31, 2020 and 2019:

	2020	2019
A. Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the Federal Affordable Care Act (Yes/No)?	<u>Yes</u>	
B. ACA fee assessment payable for the upcoming year	\$ -	\$ 43,016,618
C. ACA fee assessment paid	43,259,252	-
D. Premium written subject to ACA 9010 assessment	-	2,255,081,823
E. Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14)	265,312,464	
F. Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	265,312,464	
G. Authorized Control Level (Five-Year Historical Line 15)	66,317,250	
H. Would reporting the ACA assessment as of December 31, 2020, have triggered an RBC action level (Yes/No)?	<u>No</u>	

There are no other material non-recognized Type II events that require disclosure.

23. REINSURANCE

Reinsurance Agreements — In the normal course of business, the Company seeks to reduce potential losses that may arise from catastrophic events that cause unfavorable underwriting results by reinsuring certain levels of such risk with affiliated reinsurers. The Company remains primarily liable as the direct insurer on all risks reinsured.

The Company has an insolvency-only reinsurance agreement with UHIC. The Company remains primarily liable as the direct insurer on all risks reinsured.

The Company also had a reinsurance agreement with Unimerica Insurance Company to cede obligations related to chiropractic and physical therapy coverage, transplant coverage, infertility treatment coverage, and mental health and substance use disorder coverage. The reinsurance agreement was terminated effective December 31, 2017.

The Company does not have any unaffiliated reinsurance agreements in place as of December 31, 2020 or 2019.

Pursuant to Section 1341 of the ACA, through 2017, the Company was subject to the reinsurance provisions for compliant individual policies (see Note 24).

The effect of both internal and external reinsurance agreements outlined above on net premium income and hospital and medical expenses is presented below:

	2020	2019
Premiums:		
Direct	\$ 2,639,932,995	\$ 2,344,955,006
Ceded:		
Affiliate	<u>2,250,059</u>	<u>1,986,310</u>
Net premium income	<u>\$ 2,637,682,936</u>	<u>\$ 2,342,968,696</u>
Hospital and medical expenses:		
Direct	\$ 2,161,085,666	\$ 2,012,943,549
Ceded:		
Affiliate	(968,932)	(693,240)
Nonaffiliate	<u>-</u>	<u>36,185</u>
Net hospital and medical expenses	<u>\$ 2,162,054,598</u>	<u>\$ 2,013,600,604</u>

The Company recognized reinsurance recoveries related to internal and external reinsurance agreements of \$(968,932) and \$(657,055) in 2020 and 2019, respectively, which are recorded as net reinsurance incurred in the statutory basis statements of operations. In addition \$(108,045) and \$(1,245) for unpaid losses are recorded as a reduction to claims unpaid in 2020 and 2019, respectively, in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

A. Ceded Reinsurance Report

Section 1 — General Interrogatories

- (1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

- (2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor, or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 — Ceded Reinsurance Report — Part A

- (1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credit?

Yes () No (X)

- (2) Does the reporting entity have any reinsurance agreements in effect that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other

reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes ()

No (X)

Section 3 — Ceded Reinsurance Report — Part B

- (1) What is the estimated amount of the aggregate reduction in surplus (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of all reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

The Company estimates there should be no aggregate reduction in surplus for termination of all reinsurance agreements as of December 31, 2020.

- (2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes ()

No (X)

B. Uncollectible Reinsurance — During 2020 and 2019, there were no uncollectible reinsurance recoverables.

C. Commutation of Ceded Reinsurance — There was no commutation of reinsurance in 2020 or 2019.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation — Not applicable.

E. Reinsurance Credit

- (1) The Company has no reinsurance contracts subject to Appendix A-791 — *Life and Health Reinsurance Agreements* (“A-791”) that includes a provision which limits the reinsurer’s assumption of significant risk.
- (2) The Company has no reinsurance contracts not subject to A-791, for which reinsurance accounting was applied and which include a provision that limits the reinsurer’s assumption of risk.
- (3) The Company’s reinsurance contracts do not contain features which result in delays in payment in form or in fact.
- (4) The Company has not reflected a reinsurance accounting credit for any contracts not subject to Appendix A-791 and not yearly renewable term, which meet the risk transfer requirements of SSAP No. 61R, Life, Deposit-Type, and Accident and Health Reinsurance (“SSAP No. 61R”).
- (5) The Company did not cede any risk which is not subject to A-791 and not yearly renewable term reinsurance, under any reinsurance contract during the period covered by these financial statements, for which the statutory accounting treatment and GAAP accounting treatment were not the same.

- (6) The Company's ceded reinsurance contract which is not subject to A-791 and not yearly renewable term reinsurance, is treated the same for GAAP and statutory accounting principles.

24. RETROSPECTIVELY RATED CONTRACTS AND CONTRACTS SUBJECT TO REDETERMINATION

- A. The Company estimates accrued retrospective premium adjustments for its group health insurance business based on mathematical calculations in accordance with contractual terms.
- B. Estimated accrued retrospective premiums due to (from) the Company are recorded in premiums and considerations and aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus and as an adjustment to change in reserve for rate credits in the statutory basis statements of operations.
- C. Pursuant to the ACA, the Company's commercial business is subject to retrospectively rated features based on the actual medical loss ratios experienced on the commercial lines of business and redetermination features for premium adjustments for changes to each member's health scores based on guidelines determined by the ACA. The total amount of direct premiums written for the commercial lines of business for which a portion is subject to the retrospectively rated and redetermination features was \$6,685,544 and \$2,828,201, representing 0.3% and 0.1% of total direct premiums written as of December 31, 2020 and December 31, 2019, respectively.

Pursuant to the ACA, the Company's Medicare business is subject to retrospectively rated features based on the actual medical loss ratios experienced on the Medicare line of business and redetermination features for premium adjustments for changes to each member's health scores based on guidelines determined by CMS. The formula is calculated pursuant to the ACA guidance. The total amount of direct premiums written for the Medicare line of business for which a portion is subject to the retrospectively rated and redetermination features was \$(17,461) and \$9,355,681, representing less than 0.0% and 0.4% of total direct premiums written as of December 31, 2020 and December 31, 2019, respectively.

The Company has Medicare Part D risk-corridor amounts from CMS which are subject to a retrospectively rated feature related to Part D premiums. The Company has estimated accrued retrospective premiums related to certain Part D premiums based on guidelines determined by CMS. The formula is tiered and based on the bid medical loss ratio. The amount of Medicare Part D direct premiums written subject to the retrospectively rated feature was \$553,351, representing 0.1% of total direct premiums written as of December 31, 2019.

CMS released the final Medicaid Managed Care Rule which is subject to each State's administration elections. This rule is the first major update to the Medicaid Managed Care regulations in more than a decade, which includes a minimum loss ratio requirement. Pursuant to the regulations, premiums associated with the Company's Medicaid line of business is subject to retrospectively rated features based on the actual medical loss ratios experienced on this product. The calculation is pursuant to the Medicaid Managed Care guidance. In addition, the Company's Medicaid contract with the State is subject to retrospectively rated features under the Hepatitis C risk corridor program for which a portion of total direct premiums written is at risk. In addition, the Company's Medicaid contract with the State is subject to redetermination features for which a portion of the direct premiums written is subject to risk adjusted rating changes and for which a portion of total direct premiums written can be eligible for a performance guarantee payment base on various quality measures. The total amount of direct premiums written for the Medicaid line of business for which a portion is subject to the retrospectively rated and redetermination features was \$2,633,264,912 and \$2,332,771,124, representing 99.7% and 99.5% of total direct premiums written as of December 31, 2020 and December 31, 2019, respectively.

Effective January 1, 2020, the Company's Medicaid contract with the State includes retrospectively rated features related to the COVID-19 risk corridor program. The Company has

estimated accrued retrospective premiums pursuant to the contract. The total amount of direct premiums written for the Medicaid line of business for which a portion is subject to the retrospectively rated features was \$2,633,264,912, representing 99.7% of total direct premiums written as of December 31, 2020.

- D.** The Company is required to maintain specific minimum loss ratios on the comprehensive commercial and Medicare lines of business.

The Company's actual loss ratios on the comprehensive commercial and Medicare lines of business were in excess of the minimum requirements and as a result, no minimum medical loss ratio rebate liability was required to be established at December 31, 2020 and 2019.

Pursuant to the Medicaid Managed Care Rule, based on the State's election and state contractual minimum loss ratio requirements, the Company is required to maintain specific minimum loss ratios on its Healthy Louisiana and Healthy Louisiana populations. The Company has estimated \$0 and \$36,273,605 in estimated Medicaid Managed Care Rule and state minimum loss ratio rebates on its Medicaid, Healthy Louisiana, and Healthy Louisiana population as of December 31, 2020 and December 31, 2019, respectively, which is included in aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

E. Risk-Sharing Provisions of the Affordable Care Act

- (1)** The Company has accident and health insurance premiums in 2020 and 2019 subject to the risk-sharing provisions of the ACA.

The ACA imposed fees and premium stabilization provisions on health insurance issuers offering comprehensive commercial health insurance. The three premium stabilization programs are commonly referred to as the 3Rs — risk adjustment, reinsurance, and risk corridors.

Risk Adjustment — The permanent risk adjustment program, designed to mitigate the potential impact of adverse selection and provide stability for health insurance issuers, applies to all non-grandfathered plans not subject to transitional relief in the individual and small group markets both inside and outside of the insurance exchanges. The risk adjustments and distributions are calculated using a high-cost risk pool which adds a reinsurance-like element to this program. The operation of the high-cost risk pools excludes a percentage of costs above a threshold level determined by federal regulations. The program operates two national high-cost risk pools, one for individuals and one for small groups. The data used by CMS to determine the risk adjustment amount is subject to risk adjustment data validation audits along with the true-up to the final CMS report, which may result in a material change to arrive at the final risk adjustment amount from the initial risk adjustment estimate recorded. The risk adjustment data validation audits for 2017 and 2018 has been finalized and any adjustment from the estimate recorded is included in net premium income in the statutory basis financial statements in the period in which the amount became known. The remaining audits for the open years have not been completed. Estimates related to the open years have incorporated CMS' Final Rule on Amendments to the U.S. Department of Health & Human Services ("HHS") operated Risk Adjustment Data Validation under the ACA's HHS-operated Risk Adjustment Program published December 1, 2020 and any estimated amounts receivable from or due to CMS are included in premiums and considerations and aggregate health policy reserves, respectively, in the statutory basis statements of assets, liabilities, and capital and surplus. Premium adjustments pursuant to the risk adjustment program are accounted for as premium subject to redetermination and user fees are accounted for as assessments.

Reinsurance — The transitional reinsurance program was designed to protect issuers in the individual market from an expected increase in large claims due to the elimination of preexisting condition limitations. The transitional reinsurance program expired at the end of 2016.

Risk Corridors — The temporary risk corridors program, designed to provide some aggregate protection against variability for issuers in the individual and small group markets during the period 2014 through 2016, applied to Qualified Health Plans in the individual and small group markets both inside and outside of the insurance exchanges. The Company received \$4,452,364 from CMS for the settlement of the temporary ACA risk corridor program which has been reflected in net premium income in the statutory basis statements of operations. The details of the years impacted and the amounts received are included in Note 24E 4 and Note 24E 5 below.

- (2) The following table presents the current year impact of risk-sharing provisions of the ACA on assets, liabilities and operations:

a. Permanent ACA Risk Adjustment Program	December 31, 2020
<u>Assets</u>	
1. Premium adjustments receivable due to ACA Risk Adjustment (including high-risk pool payments)	\$ 5,407
<u>Liabilities</u>	
2. Risk adjustment user fees payable for ACA Risk Adjustment	-
3. Premium adjustments payable due to ACA Risk Adjustment (including high-risk pool premium)	2,683
<u>Operations (Revenue & Expense)</u>	
4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	3,755
5. Reported in expenses as ACA Risk Adjustment user fees (incurred/paid)	\$ (5)
b. Transitional ACA Reinsurance Program	
<u>Assets</u>	
1. Amounts recoverable for claims paid due to ACA Reinsurance	\$ -
2. Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)	-
3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	-
<u>Liabilities</u>	
4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	-
5. Ceded reinsurance premiums payable due to ACA Reinsurance	-
6. Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance	-
<u>Operations (Revenue & Expense)</u>	
7. Ceded reinsurance premiums due to ACA Reinsurance	-
8. Reinsurance recoveries (income statement) due to ACA reinsurance payments or expected payments	-
9. ACA Reinsurance contributions - not reported as ceded premium	-
c. Temporary ACA Risk Corridors Program	
<u>Assets</u>	
1. Accrued retrospective premium due to ACA Risk Corridors	\$ -
<u>Liabilities</u>	
2. Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	-
<u>Operations (Revenue & Expense)</u>	
3. Effect of ACA Risk Corridors on net premium income (paid/received)	4,452,364
4. Effect of ACA Risk Corridors on change in reserves for rate credits	-

(3) The following table is a rollforward of the prior year ACA risk-sharing provisions for asset and liability balances, along with reasons for adjustments to prior year balances:

	Accrued during the Prior Year on Business Written before December 31 of the Prior Year		Received or Paid as of the Current Year on Business Written before December 31 of the Prior Year		Differences		Adjustments		Ref	Unsettled Balances as of the Reporting Date	
					Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)
	1	2	3	4	5	6	7	8		9	10
	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)		Receivable	(Payable)
a. Permanent ACA Risk Adjustment Program											
1. Premium adjustment receivable (including high-risk pool payments)	\$ 6,381	\$ -	\$ -	\$ -	\$ 6,381	\$ -	\$ (975)	\$ -	A	\$ 5,406	\$ -
2. Premium adjustment (payable) (including high-risk pool premium)	-	(122,193)	-	(114,780)	-	(7,413)	-	4,730	B	-	(2,683)
3. Subtotal ACA Permanent Risk Adjustment Program	6,381	(122,193)	-	(114,780)	6,381	(7,413)	(975)	4,730		5,406	(2,683)
b. Transitional ACA Reinsurance Program											
1. Amounts recoverable for claims paid	-	-	-	-	-	-	-	-	C	-	-
2. Amounts recoverable for claims unpaid (contra liability)	-	-	-	-	-	-	-	-	D	-	-
3. Amounts receivable relating to uninsured plans	-	-	-	-	-	-	-	-	E	-	-
4. Liabilities for contributions payable due to ACA Reinsurance — not reported as ceded premium	-	-	-	-	-	-	-	-	F	-	-
5. Ceded reinsurance premiums payable	-	-	-	-	-	-	-	-	G	-	-
6. Liability for amounts held under uninsured plans	-	-	-	-	-	-	-	-	H	-	-
7. Subtotal ACA Transitional Reinsurance Program	-	-	-	-	-	-	-	-		-	-
c. Temporary ACA Risk Corridors Program											
1. Accrued retrospective premium	-	-	4,452,364	-	(4,452,364)	-	4,452,364	-	I	-	-
2. Reserve for rate credits or policy experience rating refunds	-	-	-	-	-	-	-	-	J	-	-
3. Subtotal ACA Risk Corridors Program	-	-	4,452,364	-	(4,452,364)	-	4,452,364	-		-	-
d. Total for ACA Risk-Sharing Provisions	\$ 6,381	\$ (122,193)	\$ 4,452,364	\$ (114,780)	\$ (4,445,983)	\$ (7,413)	\$ 4,451,389	\$ 4,730		\$ 5,406	\$ (2,683)

Explanation of Adjustments

- A. The risk adjustment receivable as of December 31, 2019 utilized paid claims through October 31, 2019. As of the Reporting Date, the risk adjustment receivable related to prior periods was adjusted based on CMS' Summary Report on Permanent Risk Adjustment Transfers for the 2019 Benefit Year. The risk adjustment receivable was further adjusted based on CMS' Summary Report of 2018 Benefit Year Risk Adjustment Data Validation Adjustments to Risk Adjustment Transfers and estimates related to the open years have incorporated CMS' Final Rule on Amendments to the HHS-operated Risk Adjustment Data Validation (HHS - RADV) under the Patient Protection and Affordable Care Act's HHS-operated Risk Adjustment Program published December 1, 2020.
- B. The risk adjustment payable as of December 31, 2019 utilized paid claims through October 31, 2019. As of the Reporting Date, the risk adjustment payable related to the prior period was adjusted based on CMS' Summary Report on Permanent Risk Adjustment Transfers for the 2019 Benefit Year. The risk adjustment payable was further adjusted based on CMS' Summary Report of 2018 Benefit Year Risk Adjustment Data Validation Adjustments to Risk Adjustment Transfers and estimates related to the open years have incorporated CMS' Final Rule on Amendments to the HHS-operated Risk Adjustment Data Validation (HHS - RADV) under the Patient Protection and Affordable Care Act's HHS-operated Risk Adjustment Program published December 1, 2020.

C. N/A

D. N/A

E. N/A

F. N/A

G. N/A

H. N/A

I. As a result of the United States Supreme Court decision on April 27, 2020 in *Maine Community Health Options vs. United States*, the Federal Government paid the full amount due to the Company under the temporary risk corridors program for the 2014, 2015, and 2016 benefit years. The risk corridor payment was recognized in the statutory basis statements of operations upon receipt in full during the quarter ended December 31, 2020.

J. N/A

- (4) The following table discloses risk corridor receivables and payables by risk corridor program year:

Risk Corridors Program Year	Accrued during the Prior Year on Business Written before December 31 of the Prior Year		Received or Paid as of the Current Year on Business Written before December 31 of the Prior Year		Differences		Adjustments		Ref	Unsettled Balances as of the Reporting Date	
	1	2	3	4	Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1 - 3 + 7)	Cumulative Balance from Prior Years (Col 2 - 4 + 8)
	Receivable	(Payable)	Receivable	(Payable)	5	6	7	8		9	10
a. 2014											
1. Accrued retrospective premium	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	A	\$ -	\$ -
2. Reserve for rate credits or policy experience rating refunds	-	-	-	-	-	-	-	-	B	-	-
b. 2015											
1. Accrued retrospective premium	-	-	4,251,826	-	(4,251,826)	-	4,251,826	-	C	-	-
2. Reserve for rate credits or policy experience rating refunds	-	-	-	-	-	-	-	-	D	-	-
c. 2016											
1. Accrued retrospective premium	-	-	200,538	-	(200,538)	-	200,538	-	E	-	-
2. Reserve for rate credits or policy experience rating refunds	-	-	-	-	-	-	-	-	F	-	-
d. Total for Risk Corridors	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 4,452,364</u>	<u>\$ -</u>	<u>\$ (4,452,364)</u>	<u>\$ -</u>	<u>\$ 4,452,364</u>	<u>\$ -</u>		<u>\$ -</u>	<u>\$ -</u>

Explanation of Adjustments

A.

B.

C. As a result of the United States Supreme Court decision on April 27, 2020 in *Maine Community Health Options vs. United States*, the Federal Government paid the full amount due to the Company under the temporary risk corridor program covering issuers of qualified health plans in the individual and small group markets for the 2015 benefit year. As of December 31, 2020, the risk corridor payment has been received and is included in net premium income in the statutory basis statements of operations.

D.

E. As a result of the United States Supreme Court decision on April 27, 2020 in *Maine Community Health Options vs. United States*, the Federal Government paid the full amount due to the Company under the temporary risk corridor program covering issuers of qualified health plans in the individual and small group markets for the 2016 benefit year. As of December 31, 2020, the risk corridor payment has been received and is included in net premium income in the statutory basis statements of operations.

F.

- (5) The following table discloses ACA risk corridor receivable balances by risk corridor program year:

Risk Corridors Program Year	1 Estimated Amount to be Filed or Final Amount Filed with CMS	2 Non-Accrued Amounts for Impairment or Other Reasons	3 Amounts Received from CMS	4 Asset Balance (Gross of Non-Admissions) (1 - 2 - 3)	5 Non-Admitted Amount	6 Net Admitted Asset (4 - 5)
a. 2014	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
b. 2015	4,251,826	-	4,251,826	-	-	-
c. 2016	<u>200,538</u>	<u>-</u>	<u>200,538</u>	<u>-</u>	<u>-</u>	<u>-</u>
d. Total (a + b + c)	<u>\$ 4,452,364</u>	<u>\$ -</u>	<u>\$ 4,452,364</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

25. CHANGE IN INCURRED CLAIMS AND CLAIMS ADJUSTMENT EXPENSES

- A. Changes in estimates related to the prior year incurred claims are included in total hospital and medical expenses in the current year in the statutory basis statements of operations. The following tables disclose paid claims, incurred claims, and the balance in claims unpaid, accrued

medical incentive pool and bonus amounts, aggregate health claim reserves, health care receivables and reinsurance recoverables for the years ended December 31, 2020 and 2019:

	2020		
	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve	\$ -	\$ (318,871,502)	\$ (318,871,502)
Paid claims — net of health care receivables and reinsurance recoveries collected	1,888,621,476	281,430,290	2,170,051,766
End of year claim reserve	<u>283,666,620</u>	<u>51,454,880</u>	<u>335,121,500</u>
Incurred claims excluding the change in health care receivables as presented below	2,172,288,096	14,013,668	2,186,301,764
Beginning of year health care receivables	-	39,360,537	39,360,537
End of year health care receivables	<u>(1,762,408)</u>	<u>(61,845,295)</u>	<u>(63,607,703)</u>
Total incurred claims	<u>\$ 2,170,525,688</u>	<u>\$ (8,471,090)</u>	<u>\$ 2,162,054,598</u>
	2019		
	Current Year Incurred Claims	Prior Years Incurred Claims	Total
Beginning of year claim reserve	\$ -	\$ (249,603,543)	\$ (249,603,543)
Paid claims—net of health care receivables and reinsurance recoveries collected	1,765,087,819	185,001,624	1,950,089,443
End of year claim reserve	<u>285,432,095</u>	<u>33,439,407</u>	<u>318,871,502</u>
Incurred claims excluding the change in health care receivables and reinsurance recoverables as presented below	2,050,519,914	(31,162,512)	2,019,357,402
Beginning of year health care receivables	-	33,603,739	33,603,739
End of year health care receivables and reinsurance recoverables	<u>(2,642,606)</u>	<u>(36,717,931)</u>	<u>(39,360,537)</u>
Total incurred claims	<u>\$ 2,047,877,308</u>	<u>\$ (34,276,704)</u>	<u>\$ 2,013,600,604</u>

The liability for claims unpaid, accrued medical incentive pool and bonus amounts, aggregate health claim reserves, net of health care receivables as of December 31, 2019 was \$279,510,965. As of December 31, 2020, \$281,430,290 has been paid for incurred claims attributable to insured events of prior years. Reserves remaining for prior years, net of health care receivables are now (\$10,390,415), as a result of re-estimation of unpaid claims. Therefore, there has been \$8,471,090 favorable prior year development since December 31, 2019 to December 31, 2020. The primary drivers consist of favorable development of favorable development as a result of a change in the provision for adverse deviations in experience of \$6,450,144, favorable development of \$2,893,934 in retroactivity for inpatient, outpatient, physician, and pharmacy claims, and offset by an unfavorable development of \$968,468 in reinsurance activity.

At December 31, 2019, the Company recorded \$34,276,704 of favorable prior year development. The primary drivers consist of favorable development of \$25,883,178 in retroactivity for inpatient, outpatient, physician, and pharmacy claims and favorable development as a result of a change in the provision for adverse deviations in experience of \$7,570,058. Original estimates are increased

or decreased, as additional information becomes known regarding individual claims, which could have an impact to the accruals for medical loss ratio rebates and retrospectively rated contracts. As a result of the prior year effects, on a regular basis, the Company adjusts revenue and the corresponding liability and/or receivable related to retrospectively rated policies and the impact of the change is included as a component of change in reserve for rate credits in the statutory basis statements of operations.

The Company incurred CAE of \$82,594,580 and \$95,129,543 in 2020 and 2019, respectively. These costs are included in the management service fees paid by the Company to UHS as a part of the Agreement (see Note 10). The following table discloses paid CAE, incurred CAE, and the balance in unpaid CAE reserve for 2020 and 2019:

	2020	2019
Total claims adjustment expenses	\$ 82,594,580	\$ 95,129,543
Less: current year unpaid claims adjustment expenses	(1,427,483)	(1,111,430)
Add: prior year unpaid claims adjustment expenses	<u>1,111,430</u>	<u>1,351,967</u>
Total claims adjustment expenses paid	<u><u>\$ 82,278,527</u></u>	<u><u>\$ 95,370,080</u></u>

- B.** The Company did not make any significant changes in methodologies and assumptions used in the calculation of the liability for claims unpaid and unpaid CAE in 2020.

26. INTERCOMPANY POOLING ARRANGEMENTS

- A–G.** The Company did not have any intercompany pooling arrangements in 2020 or 2019.

27. STRUCTURED SETTLEMENTS

- A–B.** The Company did not have structured settlements in 2020 or 2019.

28. HEALTH CARE RECEIVABLES

- A.** Pharmacy rebates receivable are recorded when reasonably estimated or billed by the affiliated pharmaceutical benefit manager in accordance with pharmaceutical rebate contract provisions. Information used to support rebates billed to the manufacturer is based on utilization information gathered by the pharmaceutical benefit manager and adjusted for significant changes in pharmaceutical contract provisions.

The Company evaluates admissibility of all pharmacy rebates receivable based on the administration of each underlying pharmaceutical benefit management agreement. The Company has nonadmitted and excluded all pharmacy rebates receivable that do not meet the admissibility criteria of SSAP No. 84, *Health Care and Government Insured Plan Receivables* (“SSAP No. 84”) from the statutory basis statements of admitted assets, liabilities, and capital and surplus.

For each pharmaceutical management agreement for which a portion of the total pharmacy rebates receivable can be admitted based on the admissibility criteria of SSAP No. 84, the pharmacy rebate transaction history is summarized as follows:

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received within 90 Days of Billing	Actual Rebates Received within 91 to 180 Days of Billing	Actual Rebates Received More than 180 Days after Billing
12/31/2020	\$ 843,212	\$ 3,995	\$ -	\$ -	\$ -
9/30/2020	860,284	751,299	488,839	-	-
6/30/2020	841,717	711,517	458,620	231,754	-
3/31/2020	1,452,617	749,765	1,855	674,194	90,470
12/31/2019	985,672	982,238	235,292	707,720	17,411
9/30/2019	532,900	996,884	201,224	109,474	666,836
6/30/2019	2,110,736	2,666,017	1,710,608	787,932	126,799
3/31/2019	5,890,908	6,014,885	3,300,991	1,715,908	890,058
12/31/2018	7,084,291	6,742,851	4,797,119	1,840,214	185,963
9/30/2018	6,505,071	6,496,554	3,843,911	2,059,957	533,626
6/30/2018	6,775,195	6,685,163	3,797,795	2,248,025	577,642
3/31/2018	6,788,436	6,537,489	3,031,387	2,776,322	689,231

Of the amount reported as health care receivables, \$1,097,992 and \$1,838,636 relates to pharmacy rebates receivable as of December 31, 2020 and 2019, respectively. This decrease is primarily due to decreased commercial membership.

B. The Company does not have any risk-sharing receivables.

The Company also admitted \$626,500 and \$975,414 of provider receivables resulting from claim overpayments as of December 31, 2020 and December 31, 2019, respectively, which are included in health care receivables in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

29. PARTICIPATING POLICIES

The Company did not have any participating contracts in 2020 or 2019.

30. PREMIUM DEFICIENCY RESERVES

The following table summarizes the Company's PDR as of December 31, 2020 and 2019:

	2020
1. Liability carried for premium deficiency reserves	\$ -
2. Date of the most recent evaluation of this liability	12/31/2020
3. Was anticipated investment income utilized in this calculation?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
	2019
1. Liability carried for premium deficiency reserves	\$ 222,333,000
2. Date of the most recent evaluation of this liability	12/31/2019
3. Was anticipated investment income utilized in this calculation?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>

PDR is included in aggregate health policy reserves in the statutory basis statements of admitted assets, liabilities, and capital and surplus.

31. ANTICIPATED SALVAGE AND SUBROGATION

Due to the type of business being written, the Company has no salvage. As of December 31, 2020 and 2019, the Company had no specific accruals established for outstanding subrogation, as it is considered a component of the actuarial calculations used to develop the estimates of claims unpaid and aggregate health claim reserves.

32. RECONCILIATION TO THE ANNUAL STATEMENT

During the audit of 2019 statutory basis financial statements, necessary adjustments were discovered during the subsequent event review related to changes in the PDR from what was previously filed by the Company to the 2019 Annual submission on March 1, 2020.

The following table reconciles the 2020 Annual Statement previously filed to the 2020 statutory basis financial statements:

	Per Audited Statutory Basis Financial Statements	Per Annual Statement	Variance
Expenses	\$ 2,470,807,505	\$ 2,465,169,505	\$ 5,638,000
Net income	105,053,768	110,691,768	(5,638,000)

The following table is also provided for additional information regarding the impact of the adjustments to 2020 net income:

Net income per annual statement	\$ 110,691,768
Adjustment to decrease in reserves for accident and health contracts	(5,638,000)
Net income per statutory basis financial statements	<u>\$ 105,053,768</u>

The result of the adjustments made to the 2020 statutory basis financial statements is a net decrease in net income of \$5,638,000.

The following table reconciles the 2019 Annual Statement previously filed to the 2019 statutory basis financial statements:

	Per Audited Statutory Basis Financial Statements	Per Annual Statement	Variance
Assets	\$ 626,088,108	\$ 627,272,088	\$ (1,183,980)
Liabilities	441,074,198	446,712,198	(5,638,000)
Capital and surplus	185,013,910	180,559,890	4,454,020
Expenses	2,299,158,018	2,327,605,018	(28,447,000)
Net income	48,916,184	20,469,184	28,447,000

The following table is also provided for additional information regarding the impact of the adjustments to capital and surplus:

Capital and surplus per annual statement	\$ 180,559,890
Change in net deferred income taxes	(1,183,980)
Adjustment to decrease in reserves for accident and health contracts	<u>5,638,000</u>
Capital and surplus per statutory basis financial statements	<u>\$ 185,013,910</u>

The following table is also provided for additional information regarding the impact of the adjustments to 2019 net income:

Net income per annual statement	\$ 20,469,184
Adjustment to decrease in reserves for accident and health contracts	<u>28,447,000</u>
Net income per statutory basis financial statements	<u>\$ 48,916,184</u>

The result of the adjustments made to the 2019 statutory basis financial statements is an increase to total capital and surplus of \$4,454,020 and an increase in net income of \$28,447,000.

* * * * *

SUPPLEMENTAL SCHEDULES

**EXHIBIT I:
SUPPLEMENTAL INVESTMENT
RISKS INTERROGATORIES**



SUPPLEMENTAL INVESTMENT RISKS INTERROGATORIES

For The Year Ended December 31, 2020
(To Be Filed by April 1)

Of The UnitedHealthcare of Louisiana, Inc.

ADDRESS (City, State and Zip Code) Minnetonka , MN 55343

NAIC Group Code 0707 NAIC Company Code 95833 Federal Employer's Identification Number (FEIN) 72-1074008

The Investment Risks Interrogatories are to be filed by April 1. They are also to be included with the Audited Statutory Financial Statements.

Answer the following interrogatories by reporting the applicable U.S. dollar amounts and percentages of the reporting entity's total admitted assets held in that category of investments.

1. Reporting entity's total admitted assets as reported on Page 2 of this annual statement. \$732,833,064

2. Ten largest exposures to a single issuer/borrower/investment.

	1	2	3	4
	Issuer	Description of Exposure	Amount	Percentage of Total Admitted Assets
2.01	BlackRock - TFFXX	Bonds	\$20,000,0002.7 %
2.02	HSBC - HGIXX	Bonds	\$14,370,1112.0 %
2.03	First American - FGZXX	Bonds	\$10,144,2511.4 %
2.04	FNMA	Bonds	\$9,934,6951.4 %
2.05	FHLMC	Bonds	\$8,102,0821.1 %
2.06	DEUTSCHE GOV - ICAXX	Bonds	\$4,268,4200.6 %
2.07	BANK OF AMERICA	Bonds	\$3,848,1310.5 %
2.08	JPMORGAN CHASE	Bonds	\$3,789,5220.5 %
2.09	CATERPILLAR INC	Bonds	\$3,607,0960.5 %
2.10	BB&T CORPORATION	Bonds	\$3,397,5490.5 %

3. Amounts and percentages of the reporting entity's total admitted assets held in bonds and preferred stocks by NAIC designation.

	Bonds	1	2		Preferred Stocks	3	4
3.01	NAIC-1	\$197,642,25627.0 %	3.07	P/RP-1	\$00.0 %
3.02	NAIC-2	\$43,783,7756.0 %	3.08	P/RP-2	\$00.0 %
3.03	NAIC-3	\$00.0 %	3.09	P/RP-3	\$00.0 %
3.04	NAIC-4	\$00.0 %	3.10	P/RP-4	\$00.0 %
3.05	NAIC-5	\$00.0 %	3.11	P/RP-5	\$00.0 %
3.06	NAIC-6	\$00.0 %	3.12	P/RP-6	\$00.0 %

4. Assets held in foreign investments:

4.01 Are assets held in foreign investments less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 4.01 above is yes, responses are not required for interrogatories 5 - 10.

4.02 Total admitted assets held in foreign investments..... \$00.0 %

4.03 Foreign-currency-denominated investments \$00.0 %

4.04 Insurance liabilities denominated in that same foreign currency \$00.0 %

SUPPLEMENT FOR THE YEAR 2020 OF THE UnitedHealthcare of Louisiana, Inc.

5. Aggregate foreign investment exposure categorized by NAIC sovereign designation:

		1	2
5.01	Countries designated NAIC-1	\$00.0 %
5.02	Countries designated NAIC-2	\$00.0 %
5.03	Countries designated NAIC-3 or below	\$00.0 %

6. Largest foreign investment exposures by country, categorized by the country's NAIC sovereign designation:

		1	2
Countries designated NAIC - 1:			
6.01	Country 1:	\$00.0 %
6.02	Country 2:	\$00.0 %
Countries designated NAIC - 2:			
6.03	Country 1:	\$00.0 %
6.04	Country 2:	\$00.0 %
Countries designated NAIC - 3 or below:			
6.05	Country 1:	\$00.0 %
6.06	Country 2:	\$00.0 %

		1	2
7.	Aggregate unhedged foreign currency exposure	\$00.0 %

8. Aggregate unhedged foreign currency exposure categorized by NAIC sovereign designation:

		1	2
8.01	Countries designated NAIC-1	\$00.0 %
8.02	Countries designated NAIC-2	\$00.0 %
8.03	Countries designated NAIC-3 or below	\$00.0 %

9. Largest unhedged foreign currency exposures by country, categorized by the country's NAIC sovereign designation:

		1	2
Countries designated NAIC - 1:			
9.01	Country 1:	\$00.0 %
9.02	Country 2:	\$00.0 %
Countries designated NAIC - 2:			
9.03	Country 1:	\$00.0 %
9.04	Country 2:	\$00.0 %
Countries designated NAIC - 3 or below:			
9.05	Country 1:	\$00.0 %
9.06	Country 2:	\$00.0 %

10. Ten largest non-sovereign (i.e. non-governmental) foreign issues:

	1	2	3	4
	Issuer	NAIC Designation		
10.01	\$00.0 %
10.02	\$00.0 %
10.03	\$00.0 %
10.04	\$00.0 %
10.05	\$00.0 %
10.06	\$00.0 %
10.07	\$00.0 %
10.08	\$00.0 %
10.09	\$00.0 %
10.10	\$00.0 %

SUPPLEMENT FOR THE YEAR 2020 OF THE UnitedHealthcare of Louisiana, Inc.

11. Amounts and percentages of the reporting entity's total admitted assets held in Canadian investments and unhedged Canadian currency exposure:

11.01 Are assets held in Canadian investments less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 11.01 is yes, detail is not required for the remainder of interrogatory 11.

		1	2
11.02 Total admitted assets held in Canadian investments	\$	0	0.0 %
11.03 Canadian-currency-denominated investments	\$	0	0.0 %
11.04 Canadian-denominated insurance liabilities	\$	0	0.0 %
11.05 Unhedged Canadian currency exposure	\$	0	0.0 %

12. Report aggregate amounts and percentages of the reporting entity's total admitted assets held in investments with contractual sales restrictions:

12.01 Are assets held in investments with contractual sales restrictions less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 12.01 is yes, responses are not required for the remainder of Interrogatory 12.

	1	2	3
12.02 Aggregate statement value of investments with contractual sales restrictions	\$	0	0.0 %
Largest three investments with contractual sales restrictions:			
12.03	\$	0	0.0 %
12.04	\$	0	0.0 %
12.05	\$	0	0.0 %

13. Amounts and percentages of admitted assets held in the ten largest equity interests:

13.01 Are assets held in equity interests less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 13.01 above is yes, responses are not required for the remainder of Interrogatory 13.

	1 Issuer	2	3
13.02	\$	0	0.0 %
13.03	\$	0	0.0 %
13.04	\$	0	0.0 %
13.05	\$	0	0.0 %
13.06	\$	0	0.0 %
13.07	\$	0	0.0 %
13.08	\$	0	0.0 %
13.09	\$	0	0.0 %
13.10	\$	0	0.0 %
13.11	\$	0	0.0 %

SUPPLEMENT FOR THE YEAR 2020 OF THE UnitedHealthcare of Louisiana, Inc.

14. Amounts and percentages of the reporting entity's total admitted assets held in nonaffiliated, privately placed equities:

14.01 Are assets held in nonaffiliated, privately placed equities less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 14.01 above is yes, responses are not required for 14.02 through 14.05.

	1	2	3
14.02 Aggregate statement value of investments held in nonaffiliated, privately placed equities	\$00.0 %	
Largest three investments held in nonaffiliated, privately placed equities:			
14.03	\$00.0 %	
14.04	\$00.0 %	
14.05	\$00.0 %	

Ten largest fund managers:

	1	2	3	4
	Fund Manager	Total Invested	Diversified	Nondiversified
14.06		\$0	\$0	\$0
14.07		\$0	\$0	\$0
14.08		\$0	\$0	\$0
14.09		\$0	\$0	\$0
14.10		\$0	\$0	\$0
14.11		\$0	\$0	\$0
14.12		\$0	\$0	\$0
14.13		\$0	\$0	\$0
14.14		\$0	\$0	\$0
14.15		\$0	\$0	\$0

15. Amounts and percentages of the reporting entity's total admitted assets held in general partnership interests:

15.01 Are assets held in general partnership interests less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 15.01 above is yes, responses are not required for the remainder of Interrogatory 15.

	1	2	3
15.02 Aggregate statement value of investments held in general partnership interests	\$00.0 %	
Largest three investments in general partnership interests:			
15.03	\$00.0 %	
15.04	\$00.0 %	
15.05	\$00.0 %	

SUPPLEMENT FOR THE YEAR 2020 OF THE UnitedHealthcare of Louisiana, Inc.

16. Amounts and percentages of the reporting entity's total admitted assets held in mortgage loans:

16.01 Are mortgage loans reported in Schedule B less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 16.01 above is yes, responses are not required for the remainder of Interrogatory 16 and Interrogatory 17.

	1 Type (Residential, Commercial, Agricultural)	2	3
16.02	\$00.0 %
16.03	\$00.0 %
16.04	\$00.0 %
16.05	\$00.0 %
16.06	\$00.0 %
16.07	\$00.0 %
16.08	\$00.0 %
16.09	\$00.0 %
16.10	\$00.0 %
16.11	\$00.0 %

Amount and percentage of the reporting entity's total admitted assets held in the following categories of mortgage loans:

		Loans	
16.12	Construction loans	\$00.0 %
16.13	Mortgage loans over 90 days past due	\$00.0 %
16.14	Mortgage loans in the process of foreclosure	\$00.0 %
16.15	Mortgage loans foreclosed	\$00.0 %
16.16	Restructured mortgage loans	\$00.0 %

17. Aggregate mortgage loans having the following loan-to-value ratios as determined from the most current appraisal as of the annual statement date:

Loan to Value	Residential		Commercial		Agricultural	
	1	2	3	4	5	6
17.01 above 95%.....	\$00.0 %	\$00.0 %	\$00.0 %
17.02 91 to 95%.....	\$00.0 %	\$00.0 %	\$00.0 %
17.03 81 to 90%.....	\$00.0 %	\$00.0 %	\$00.0 %
17.04 71 to 80%.....	\$00.0 %	\$00.0 %	\$00.0 %
17.05 below 70%.....	\$00.0 %	\$00.0 %	\$00.0 %

18. Amounts and percentages of the reporting entity's total admitted assets held in each of the five largest investments in real estate:

18.01 Are assets held in real estate reported less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 18.01 above is yes, responses are not required for the remainder of Interrogatory 18.

Largest five investments in any one parcel or group of contiguous parcels of real estate.

	Description 1	2	3
18.02	\$00.0 %
18.03	\$00.0 %
18.04	\$00.0 %
18.05	\$00.0 %
18.06	\$00.0 %

19. Report aggregate amounts and percentages of the reporting entity's total admitted assets held in investments held in mezzanine real estate loans:

19.01 Are assets held in investments held in mezzanine real estate loans less than 2.5% of the reporting entity's total admitted assets? Yes [X] No []

If response to 19.01 is yes, responses are not required for the remainder of Interrogatory 19.

	1	2	3
19.02	Aggregate statement value of investments held in mezzanine real estate loans:	\$00.0 %
	Largest three investments held in mezzanine real estate loans:		
19.03	\$00.0 %
19.04	\$00.0 %
19.05	\$00.0 %

SUPPLEMENT FOR THE YEAR 2020 OF THE UnitedHealthcare of Louisiana, Inc.

20. Amounts and percentages of the reporting entity's total admitted assets subject to the following types of agreements:

		At Year End		1st Quarter		At End of Each Quarter		3rd Quarter	
		1	2	3		4		5	
20.01	Securities lending agreements (do not include assets held as collateral for such transactions)	\$00.0 %	\$0		\$0		\$0	
20.02	Repurchase agreements	\$00.0 %	\$0		\$0		\$0	
20.03	Reverse repurchase agreements	\$00.0 %	\$0		\$0		\$0	
20.04	Dollar repurchase agreements	\$00.0 %	\$0		\$0		\$0	
20.05	Dollar reverse repurchase agreements	\$00.0 %	\$0		\$0		\$0	

21. Amounts and percentages of the reporting entity's total admitted assets for warrants not attached to other financial instruments, options, caps, and floors:

		Owned		Written	
		1	2	3	4
21.01	Hedging	\$00.0 %	\$00.0 %
21.02	Income generation	\$00.0 %	\$00.0 %
21.03	Other	\$00.0 %	\$00.0 %

22. Amounts and percentages of the reporting entity's total admitted assets of potential exposure for collars, swaps, and forwards:

		At Year End		1st Quarter		At End of Each Quarter		3rd Quarter	
		1	2	3		4		5	
22.01	Hedging	\$00.0 %	\$0		\$0		\$0	
22.02	Income generation	\$00.0 %	\$0		\$0		\$0	
22.03	Replications	\$00.0 %	\$0		\$0		\$0	
22.04	Other	\$00.0 %	\$0		\$0		\$0	

23. Amounts and percentages of the reporting entity's total admitted assets of potential exposure for futures contracts:

		At Year End		1st Quarter		At End of Each Quarter		3rd Quarter	
		1	2	3		4		5	
23.01	Hedging	\$00.0 %	\$0		\$0		\$0	
23.02	Income generation	\$00.0 %	\$0		\$0		\$0	
23.03	Replications	\$00.0 %	\$0		\$0		\$0	
23.04	Other	\$00.0 %	\$0		\$0		\$0	

EXHIBIT II:
SUMMARY INVESTMENT SCHEDULE

ANNUAL STATEMENT FOR THE YEAR 2020 OF THE UnitedHealthcare of Louisiana, Inc.

SUMMARY INVESTMENT SCHEDULE

Investment Categories	Gross Investment Holdings		Admitted Assets as Reported in the Annual Statement			
	1 Amount	2 Percentage of Column 1 Line 13	3 Amount	4 Securities Lending Reinvested Collateral Amount	5 Total (Col. 3 + 4) Amount	6 Percentage of Column 5 Line 13
1. Long-Term Bonds (Schedule D, Part 1):						
1.01 U.S. governments	23,697,152	4.678	23,697,152	0	23,697,152	4.678
1.02 All other governments	0	0.000	0	0	0	0.000
1.03 U.S. states, territories and possessions, etc. guaranteed	13,913,042	2.746	13,913,042	0	13,913,042	2.746
1.04 U.S. political subdivisions of states, territories, and possessions, guaranteed	25,714,460	5.076	25,714,460	0	25,714,460	5.076
1.05 U.S. special revenue and special assessment obligations, etc. non-guaranteed	55,559,375	10.967	55,559,375	0	55,559,375	10.967
1.06 Industrial and miscellaneous	122,542,002	24.189	122,542,002	0	122,542,002	24.189
1.07 Hybrid securities	0	0.000	0	0	0	0.000
1.08 Parent, subsidiaries and affiliates	0	0.000	0	0	0	0.000
1.09 SVO identified funds	0	0.000	0	0	0	0.000
1.10 Unaffiliated Bank loans	0	0.000	0	0	0	0.000
1.11 Total long-term bonds	241,426,031	47.655	241,426,031	0	241,426,031	47.655
2. Preferred stocks (Schedule D, Part 2, Section 1):						
2.01 Industrial and miscellaneous (Unaffiliated)	0	0.000	0	0	0	0.000
2.02 Parent, subsidiaries and affiliates	0	0.000	0	0	0	0.000
2.03 Total preferred stocks	0	0.000	0	0	0	0.000
3. Common stocks (Schedule D, Part 2, Section 2):						
3.01 Industrial and miscellaneous Publicly traded (Unaffiliated)	0	0.000	0	0	0	0.000
3.02 Industrial and miscellaneous Other (Unaffiliated)	0	0.000	0	0	0	0.000
3.03 Parent, subsidiaries and affiliates Publicly traded	0	0.000	0	0	0	0.000
3.04 Parent, subsidiaries and affiliates Other	0	0.000	0	0	0	0.000
3.05 Mutual funds	0	0.000	0	0	0	0.000
3.06 Unit investment trusts	0	0.000	0	0	0	0.000
3.07 Closed-end funds	0	0.000	0	0	0	0.000
3.08 Total common stocks	0	0.000	0	0	0	0.000
4. Mortgage loans (Schedule B):						
4.01 Farm mortgages	0	0.000	0	0	0	0.000
4.02 Residential mortgages	0	0.000	0	0	0	0.000
4.03 Commercial mortgages	0	0.000	0	0	0	0.000
4.04 Mezzanine real estate loans	0	0.000	0	0	0	0.000
4.05 Total valuation allowance	0	0.000	0	0	0	0.000
4.06 Total mortgage loans	0	0.000	0	0	0	0.000
5. Real estate (Schedule A):						
5.01 Properties occupied by company	0	0.000	0	0	0	0.000
5.02 Properties held for production of income	0	0.000	0	0	0	0.000
5.03 Properties held for sale	0	0.000	0	0	0	0.000
5.04 Total real estate	0	0.000	0	0	0	0.000
6. Cash, cash equivalents and short-term investments:						
6.01 Cash (Schedule E, Part 1)	52,653	0.010	52,653	0	52,653	0.010
6.02 Cash equivalents (Schedule E, Part 2)	262,697,267	51.854	262,697,267	0	262,697,267	51.854
6.03 Short-term investments (Schedule DA)	0	0.000	0	0	0	0.000
6.04 Total cash, cash equivalents and short-term investments	262,749,920	51.864	262,749,920	0	262,749,920	51.864
7. Contract loans	0	0.000	0	0	0	0.000
8. Derivatives (Schedule DB)	0	0.000	0	0	0	0.000
9. Other invested assets (Schedule BA)	2,434,863	0.481	2,434,863	0	2,434,863	0.481
10. Receivables for securities	0	0.000	0	0	0	0.000
11. Securities Lending (Schedule DL, Part 1)	0	0.000	0	XXX	XXX	XXX
12. Other invested assets (Page 2, Line 11)	0	0.000	0	0	0	0.000
13. Total invested assets	506,610,814	100.000	506,610,814	0	506,610,814	100.000

**EXHIBIT III:
SUPPLEMENTAL SCHEDULE
REGARDING REINSURANCE CONTRACTS
WITH RISK-LIMITING FEATURES**

UNITEDHEALTHCARE OF LOUISIANA, INC.

FOR THE YEAR ENDED DECEMBER 31, 2020 SUPPLEMENTAL SCHEDULE OF THE ANNUAL AUDIT REPORT SUPPLEMENTAL SCHEDULE REGARDING REINSURANCE CONTRACTS WITH RISK-LIMITING FEATURES

Reinsurance contracts subject to Appendix A-791 — *Life and Health Reinsurance Agreements of the NAIC Accounting Practices and Procedures Manual*:

The Company has no reinsurance contracts subject to Appendix A-791 – Life and Health Reinsurance Agreements (“A-791”) that includes a provision which limits the reinsurer’s assumption of significant risk.

Reinsurance contracts NOT subject to Appendix A-791 — *Life and Health Reinsurance Agreements of the NAIC Accounting Practices and Procedures Manual*:

The Company has no reinsurance contracts not subject to A-791, for which reinsurance accounting was applied and which include a provision that limits the reinsurer’s assumption of risk.

Payments to reinsurers (excluding reinsurance contracts with a federal or state facility):

The Company’s reinsurance contracts do not contain features which result in delays in payment in form or in fact.

Reinsurance contracts NOT subject to Appendix A-791 — *Life and Health Reinsurance Agreements of the NAIC Accounting Practices and Procedures Manual* and NOT yearly-renewable term that meet the risk transfer requirements under SSAP No. 61R:

The Company has not reflected a reinsurance accounting credit for any contracts not subject to Appendix A-791 and not yearly renewable term, which meet the risk transfer requirements of SSAP No. 61R, *Life, Deposit-Type, and Accident and Health Reinsurance* (“SSAP No. 61R”).

The Company did not cede any risk which is not subject to A-791 and not yearly renewable term reinsurance, under any reinsurance contract during the period covered by these financial statements, for which the statutory accounting treatment and GAAP accounting treatment were not the same.

The Company’s ceded reinsurance contract which are not subject to A-791 and not yearly renewable term reinsurance, is treated the same for GAAP and statutory accounting principles.

OTHER ATTACHMENT

To the Audit Committee of
UnitedHealthcare of Louisiana, Inc.
3838 N. Causeway Boulevard, Suite 2600
Metairie, LA 70002

The Management of
UnitedHealthcare of Louisiana, Inc.
3838 N. Causeway Boulevard, Suite 2600
Metairie, LA 70002

Dear Members of the Audit Committee and Management:

We have audited, in accordance with auditing standards generally accepted in the United States of America, the statutory-basis financial statements of UnitedHealthcare of Louisiana, Inc. (the "Company") for the years ended December 31, 2020, and 2019, and have issued our report thereon dated April 16, 2021. In connection therewith, we advise you as follows:

1. We are independent certified public accountants with respect to the Company and conform to the standards of the accounting profession as contained in the *Code of Professional Conduct* and pronouncements of the American Institute of Certified Public Accountants, the rules and regulations of the Louisiana Department of Insurance, and the Rules of Professional Conduct of the Minnesota State Board of Accountancy.
2. The engagement partner and engagement manager, who are certified public accountants, have 16 years and 8 years, respectively, of experience in public accounting and are experienced in auditing insurance enterprises. Members of the engagement team, most of whom have had experience in auditing insurance enterprises and 32 percent of whom are certified public accountants, were assigned to perform tasks commensurate with their training and experience.
3. We understand that the Company intends to file its audited statutory-basis financial statements and our report thereon with the Louisiana Department of Insurance and other state insurance departments in states in which the Company is licensed and that the insurance commissioners of those states will be relying on that information in monitoring and regulating the statutory-basis financial condition of the Company.

While we understand that an objective of issuing a report on the statutory-basis financial statements is to satisfy regulatory requirements, our audit was not planned to satisfy all objectives or responsibilities of insurance regulators. In this context, the Company and insurance commissioners should understand that the objective of an audit of statutory-basis financial statements in accordance with auditing standards generally accepted in the United States of America is to form an opinion and issue a report on whether the statutory-basis financial statements present fairly, in all material respects, the admitted assets, liabilities, and capital and surplus, results of operations and cash flows in accordance with accounting practices prescribed or permitted by the Louisiana Department of Insurance. Consequently, under auditing standards generally accepted in the United States of America, we have the responsibility, within the inherent limitations of the auditing process, to plan and perform our audit to obtain reasonable assurance regarding whether the statutory-basis financial statements are free from material misstatement, whether due to error or fraud, and to exercise due professional care in the conduct of the audit. The Company is not required to have, nor were we

engaged to perform, an audit of internal control over financial reporting. Our audit included consideration of internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of internal control over financial reporting. The concept of selective testing of the data being audited, which involves judgment both as to the number of transactions to be audited and the areas to be tested, has been generally accepted as a valid and sufficient basis for an auditor to express an opinion on financial statements. Audit procedures that are effective for detecting errors, if they exist, may be ineffective for detecting misstatements resulting from fraud. Because of the characteristics of fraud, particularly those involving concealment and falsified documentation (including forgery), a properly planned and performed audit may not detect a material misstatement resulting from fraud. In addition, an audit does not address the possibility that material misstatements may occur in the future. Also, our use of professional judgment and the assessment of materiality for the purpose of our audit mean that matters may exist that would have been assessed differently by insurance commissioners.

It is the responsibility of the management of the Company to adopt sound accounting policies, to maintain an adequate and effective system of accounts, and to establish and maintain internal control that will, among other things, provide reasonable, but not absolute, assurance that assets are safeguarded against loss from unauthorized use or disposition and that transactions are executed in accordance with management's authorization and are recorded properly to permit the preparation of financial statements in conformity with accounting practices prescribed or permitted by the Louisiana Department of Insurance.

The Insurance Commissioner should exercise due diligence to obtain whatever other information that may be necessary for the purpose of monitoring and regulating the statutory basis financial position of insurers and should not rely solely on the independent auditors' report.

4. We will retain the working papers (including those kept in a hard copy or electronic medium) prepared in the conduct of our audit until the Louisiana Department of Insurance has filed a Report of Examination covering 2020, but no longer than seven years. After notification to the Company, we will make the working papers available for review by the Louisiana Department of Insurance or its delegates, at the offices of the insurer, at our offices, at the Louisiana Department of Insurance, or at any other reasonable place designated by the Insurance Commissioner. Furthermore, in the conduct of the aforementioned periodic review by the Louisiana Department of Insurance, photocopies of pertinent audit working papers may be made (under the control of Deloitte & Touche LLP) and such copies may be retained by the Louisiana Department of Insurance. In addition, to the extent requested, we may provide the Louisiana Department of Insurance with copies of certain audit working papers (such as unlocked copies of Excel spreadsheets that do not contain password protection or encryption). As such, these audit working papers will be subject to potential modification by Louisiana Department of Insurance or by others. We are not responsible for any modifications made to the copies, electronic or otherwise, after they are provided to the Louisiana Department of Insurance; and we are likewise not responsible for any effect that any such modifications, whether intentional or not, might have on the process, substance, or outcome of your regulatory examination.
5. The engagement partner has served in this capacity with respect to the Company since 2019, is licensed by the Minnesota State Board of Accountancy, and is a member in good standing of the American Institute of Certified Public Accountants.

6. To the best of our knowledge and belief, we are in compliance with the requirements of section 7 of the *NAIC's Model Rule (Regulation) Requiring Annual Audited Financial Reports* regarding qualifications of independent certified public accountants.

This letter is intended solely for the information and use of the Audit Committee and management of UnitedHealthcare of Louisiana, Inc. and for filing with the Louisiana Department of Insurance and other state insurance departments to whose jurisdiction the Company is subject and is not intended to be and should not be used by anyone other than these specified parties.

Deloitte + Touche LLP

April 16, 2021